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Effect of Pentacyclic Triterpenes Found in Perilla frutescens Alone or in 
Combination with Resveratrol on Skin Tumor Promotion by 12-O-tetra-
decanoylphorbol-13-acetate 
 
Jiyoon Cho, Ph.D. 
The University of Texas at Austin, 2015 
Supervisor: John DiGiovanni 
 
A series of pentacyclic triterpenes found in P. frutescens, including ursolic acid 
(UA), oleanolic acid (OA), augustic acid (AA), corosolic acid (CA), 3-epi-corosolic acid 
(3-epiCA), maslinic acid (MA), and 3-epi-maslinic acid (3-epiMA) were evaluated for 
their effects on skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate (TPA). 
UA was also evaluated in a combination with resveratrol (Res) for possible 
combinatorial chemopreventive activity. 
 
All triterpene compounds significantly inhibited skin tumor promotion by TPA. MA 
and 3-epiCA, were significantly more effective than UA at inhibiting tumor development. 
Topical pretreatment with all of these compounds significantly inhibited epidermal 
proliferation induced by TPA, however, CA, 3-epiCA and MA were more effective than 
UA. All compounds reduced skin inflammation and inflammatory gene expression 
induced by TPA, however, 3-epiCA and MA were identified to be more effective than UA. 
Finally, the ability of these compounds to alter epidermal signaling pathways associated 
with skin tumor promotion by TPA was also evaluated. The greater ability of 3-epiCA 
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and MA to inhibit skin tumor promotion was associated with greater reduction of Cox-2 
and Twist1 proteins and inhibition of activation of IGF-1R, Stat3 and Src.  
 
The effect of combining UA + Res for combinatorial inhibitory effects on skin 
tumor promotion were also examined. The combination of UA + Res produced a greater 
inhibition of TPA-induced epidermal hyperproliferation, epidermal inflammatory 
signaling, and inflammatory gene expression when compared to UA or Res alone. 
Furthermore, NF-B, Egr-1, and AP-1 DNA binding activities following TPA treatment 
were dramatically decreased by the combination of UA + Res. Treatment with UA + Res 
during skin tumor promotion by TPA produced greater inhibition of tumor multiplicity and 
tumor size than with either agent alone.  
  
Collectively, the current data demonstrate that UA and related triterpenes as well 
as the combination of UA + Res inhibited skin tumor promotion by TPA via effects on 
multiple cellular and biochemical/molecular mechanisms associated with this process 
similar to calorie restriction. Of the tritperpenes tested, 3-epiCA and MA were the most 
active. Furthermore, the favorable anti-tumor promoting effects of combining UA + Res 
suggest that phytochemical combination therapy may be a more efficacious strategy for 
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Chapter 1: Introduction and background 
1.1 Cancer chemoprevention 
According to the American Cancer Society, there will be an estimated 1,665,540 new 
cancer cases diagnosed and 585,720 cancer deaths in the US in 2014. In addition, 
cancer remains the second most common cause of death in the US, accounting for nearly 
1 of every 4 deaths [1]. Even though there is no magic cure to conquer cancer, many 
types of cancers can be mitigated. Cancer risks can be reduced by eliminating or 
minimizing exposure to carcinogens. In addition, it is estimated that more than one 
third of cancer deaths in the United States can be avoided by controlling nutritional 
factors and diet [2, 3]. Evidence suggests that dietary components can reduce 
cancer risk. For example, epidemiological studies have shown that fruit and 
vegetable intake significantly reduced many types of cancers including, lung, colon, 
breast, cervix, esophagus, stomach, oral cavity, pancreas, and bladder, and ovary [4]. 
Thus, preventing cancer by controlling the diet may be an effective strategy for 
controlling cancer.  
 
Given a constant increase in cancer incidence and limitations in cancer treatment, 
there has been increased interest in studying cancer prevention. In the mid-1970s, 
Michael Sporn created the term „chemoprevention‟, which is defined as the use of 
natural or synthetic agents to reverse, inhibit or slow the beginning or later stages of 
carcinogenesis. For the last several decades, a number of cancer chemopreventive 
agents have been identified and shown to inhibit either tumor initiation and/or 
promotion [5, 6]. Compounds such as ellagic acid and indole-3-carbinol inhibit 
cancer initiation by pro-carcinogens which are converted to ultimate carcinogens via 





agents in cancer prevention may involve inhibition of direct interaction of pro-
carcinogen with DNA, enhancement of detoxification of pro-carcinogen, and 
decrease in metabolism of pro-carcinogen to be activated [6-8]. Also, blocking 
agents may scavenge free radicals, alter DNA repair, and modulate DNA methyl 
transferases [9]. Cancer suppressing agents inhibit later stages of carcinogenesis 
including tumor promotion and progression. They suppress signal transduction 
pathways (e.g., EGFR, NF-B, AP-1, -catenin, and STAT3) which are often 
dysregulated by tumor promoters [6, 9]. In addition, mechanisms of the tumor 
suppressing agents include decreasing inflammatory gene expression (e.g., 
chemokines, COX-2, IL-12, TNF-, and IL-6), inhibition of cell proliferation, and 
induction of apoptosis in pre-neoplastic lesions [6, 9]. Recently, emerging evidence 
has suggested that activating AMPK and decreasing mTOR signaling pathways may 
be a good strategy for cancer chemoprevention by suppressing agents [10-12].  
 
1.2 Two-stage skin carcinogenesis model 
The two-stage skin carcinogenesis model is a chemically-induced model of epithelial 
carcinogenesis that enables evaluation of all stages of tumor development, including 
tumor initiation, promotion, and progression [13, 14]. This well-established model for 
studying sequential development of tumors can be used to evaluate cancer 
chemopreventive agents for their effects on the carcinogenesis process.  
In the two-stage skin carcinogenesis protocol, a single topical application of a 
carcinogen induces irreversible DNA mutation in H-ras and K-ras genes in 
keratinocyte stem cells [14-17]. DMBA (7,12-dimethylbenz[a]anthracene) is the most 





that keratinocyte stem cells in the bulge region of the hair follicles are the primary 
cellular target for the initiation stage [18].  
 
After initiation, repeated topical application of a tumor promoting agent (i.e., TPA) 
leads to skin tumor development. During this promotion stage, the number of 
nucleated cell layers and epidermal thickness are increased [14, 19, 20] referred to 
as hyperplasia. In addition, keratinocyte proliferation is significantly increased. 
Initiated cells progress to clonal outgrowths of skin and eventually become 
papillomas [14, 19, 20]. In the progression stage, papillomas convert to squamous 
cell carcinomas as early as 20 weeks of tumor promotion with additional stochastic 
genetic change, loss of heterozygosity, aneuploidy, and dysplasia. The malignant 
carcinoma have the capacity to invade the basement membrane and to metastasize 







Figure 1-1. Two-stage model of skin carcinogenesis in mice. During initiation, topical 
application of a sub-carcinogenic dose of a mutagenic agent induces mutations in target 
genes in keratinocyte stem cells. Repeated topical application of a promoting agent 
begins 2 weeks after initiation and continues for the duration of the study. Papillomas 
begin to arise after ~6-12 weeks of promotion and a fraction begin to convert to 
squamaous cell carcinoma (SCC) after ~ 20 weeks. Representative H&E stained sections 
of normal skin, hyperplastic skin, a papilloma and SCC are presented. All mice were 
handled in accordance with institutional and national regulations.  Adapted from Nature 
Protocol [14] : Abel, E.L., et al., Multi-stage chemical carcinogenesis in mouse skin: 



















1.2.1 Cellular and biochemical mechanisms of skin tumor promotion 
During skin tumor promotion, activation of cellular mechanisms involving induction of 
a sustained proliferation and skin inflammation (e.g., dermal infiltration of  
inflammatory cells) are critical for skin carcinogenesis. Maintenance of sustained 
proliferation and inflammation as well as activation of oncogenic signaling pathways 
is required. Signaling pathways known to be upregulated by tumor promoters include 
growth factor receptor signaling pathways, cell cycle signaling, and inflammatory 
signaling pathways. [13, 14, 21].  
 
Hyperproliferation and infiltration of inflammatory cells 
During the tumor promotion stage, repeated topical treatments of TPA produce and 
maintain chronic epidermal cell proliferation [13]. Initiated cells show a differential 
response to the mitogenic stimulant, TPA, and clonally expand to form pre-malignant 
papillomas [13, 14, 21]. Another important aspect of tumor promotion is chronic 
inflammation. Secretion of pro-inflammatory molecules resulting from TPA treatment 
recruits inflammatory cells such as mast cells, monocytes, leukocytes, T-
lymphocytes, B-lymphocytes, and macrophages into the dermis [22, 23]. The 
number of inflammatory cells increase in the dermis and also promote tumor growth 
by producing growth factors, cytokines, and chemokines [22, 23]. 
 
Receptor tyrosine kinases – EGFR and IGF-1R 
i) Epidermal growth factor receptor (EGFR) 
Epidermal growth factor (EGF) is a mitogen that binds to EGFR and activates growth 
signaling pathways involved in proliferation of epidermal keratinocytes [21]. Activated 





expression are observed in skin cancer as well as other cancers including lung, 
breast and ovarian cancers [24-26] .  
 
The ErbB family is a transmembrane receptor tryrosine kinase family that includes 
EGFR (or ErbB1), ErbB2, ErbB3, and ErbB4. This receptor family can form homo- or 
heteromiders upon ligand binding to the extracellular domain and activate the kinase 
catalytic domain resulting in activation of downstream signaling through 
phosphorylation of other kinases, adaptor proteins or transcriptional factor [26]. 
Multiple ligands can activate the EGFR pathway including EGF, transforming growth 
factor-a (TGF-), heparin-binding EGF-like growth factor (HB-EGF), amphiregulin, 
and betacelullin [27, 28]. The ligand binding to receptor allows EGFR form a homo- 
and/or heterodimers with ErbB2 and induces autophosphorylation of tyrosine kinases 
in the cytoplasmic tails [27, 28].  
 
EGFR is constitutively upregulated in skin papillomas and carcinomas induced by 
the two-stage protocol [29]. Multiple applications of tumor promoters (e.g., TPA or 
chrysarobin) increases the expression of multiple ligands such as TGF-, EGF, and 
amphiregulin which activates the EGFR signaling pathway during tumor promotion 
(Figure 1-2) [29]. Transgenic mice overexpressing TGF- are more susceptible to 
skin tumor development while mice with a spontaneous inactivating mutation in TGF-
 gene were resistant to tumor development using the two stage skin carcinogenesis 
protocol [30-32]. Similarly, ErbB2 transgenic mice are highly sensitive to TPA-
induced epidermal hyperproliferation and two-stage skin carcinogenesis [33]. Also, 





















ii) Insulin-like growth factor-1 receptor (IGF-1R) 
IGF-1 is a polypeptide with structure similar to proinsulin. IGF-1 binds to its receptor 
(IGF-1R) which is a receptor tyrosine kinase [34-36]. IGF-1 binding to the 
extracellular  subunit of IGF-1R results in autophosphorylation of the cytoplasmic 
tyrosine kinase domain in the transmembrane  subunit which leads to 
phosphorylation of a number of target proteins that bind to specific phosphorylated 
tyrosine residues, including insulin receptor substrate-1 (IRS-1), IRS-2, Shc, and Crk  
(see again Figure 1-2) [34-36]. Activated IRS-1 and /or Shc propagate signaling 
through PI3K/Akt/mTOR or Ras/Raf/MAPK pathways for anti-apoptosis, protein 
synthesis, cell proliferation, and cell survival [34-36]. 
 
The importance of IGF-1R signaling has been emphasized in various cancer models 
including, lung, breast, and colon. In the mouse skin model, the mRNA level of IGF-1 
transcripts was found to be upregulated in both skin papillomas and carcinomas 
while very low levels of the mRNA were detectable in normal skin [37]. Accumulated 
data have shown that IGF-1 is important for both initiation and promotion in skin 
tumorigenesis [38-41]. For example, BK5.IGF-1 transgenic mice overexpressing 
IGF-1 in the epidermis showed epidermal hyperplasia and hypersensitivity to two-
stage carcinogenesis [39]. HK1.IGF-1 mice produced rapid tumor development in 
response to diverse classes of tumor promoters including chrysarobin, okadaic acid, 
and benzoyl peroxide when compared to wild-type mice [41]. In addition, 
spontaneous tumors with or without initiation were observed in BK5.IGF-1 mice [39]. 
On the other hand, liver-specific IGF-1 deficient (LID) mice, which have reduced 






Overall, these data suggest that activation of receptor tyrosine kinsases such as 
EGFR and IGF-1R is important for tumor promoter-induced epidermal 
hyperproliferation and skin tumor promotion. Also, intervention of these signaling 
pathways might be a good strategy for cancer prevention. 
 
Proinflammatory cytokines 
Cytokines are small proteins that mediate immune response and control various 
cellular functions including proliferation, differentiation and cell survival/apoptosis 
[42]. Cytokines are produced in response to inflammatory stimuli by a variety of cells 
of both the innate (e.g., monocytes and macrophages) and adaptive (e.g., T- and B-
cells) immune systems. In addition, epithelial cells can produce cytokines in 
response to such stimuli. Depending on the tumor microenvironment, some 
cytokines can induce anti-tumorigenic responses. However, under chronic 
inflammation conditions, they can cause cell transformation, malignancy, and an 
imbalance between anti-inflammatory cytokines (e.g., IL-10, IL-4, IL-13 and IL-5) and 
pro-inflammatory cytokines (IFNγ, IL-1, IL-6 and TNF-α) which can lead to tumor 
development [43, 44].  
 
Cytokines including TNF-, IL-1, IL-6, IL-17, IL-22, and IL-23 can contribute to skin 
tumor development [21]. Their expression level is increased in response to tumor 
promoters such as TPA and okadaic acid, and binding to their receptors leads to 
propagation of signaling pathways involved in cell apoptosis, survival, inflammation, 
proliferation, and differentiation for tumor development [21]. For example, tumor 





and TNFR2 [45, 46]. Ligand-bound TNFRs recruit various adaptor proteins such as 
TNFR1-associated death domain protein (TRADD), receptor interacting protein 
kinase (RIP), and TNFR-associated factor-2 (TRAF2) [46]. The recruited proteins 
then activate the following signaling pathways; 1) FADD-Caspase-8/10 for apoptosis, 
2) IKK/IB/NF-B pathway for inflammation and cell survival, and 3) 
GCK/MKK7/4/JNK-AP-1 or ROS/ASK1/MKK7/4/JNK/AP-1 for gene expression, cell 
proliferation, and differentiation (see Figure 1-3) [46].  
 
Interleukins are also important for tumor development. They are produced by many cell 
types including leukocytes [47]. Several interleukins have been shown to have a clear role 
in skin tumor promotion. The expression level of IL-1 and IL- are increased in response 
to TPA treatment in vitro and in vivo [48-50]. IL-1 binds to IL-1R which recruits a 
transmembrane receptor accessory protein (IL-1RAcP) to propagate signals through IL-
1R-associated kinase (IRAK)-NF-B signaling for inflammation  (see Figure 1-3) [51, 52]. 
In the skin carcinogenesis model, mice overexpressing IL-1 in basal keratinocytes 
develop spontaneous skin inflammation and dermal neutrophil infiltration [53]. Also DMBA 
treatment increased mRNA levels of IL-1 and it is also upregulated in both skin 
papillomas and carcinomas when compared to normal skin [54]. IL-1Ra is an endogenous 
receptor antagonist and is increased in TPA-induced mouse keratinocytes in vitro as well 
as both in papillomas and carcinomas [54]. In addition, La et al. reported that even though 
overexpression of IL-1Ra in a skin carcinoma cell line (icIL-1Ra-JWF2 cells) did not 
change IL-1 mRNA levels, these transfected cells had a decreased growth rate 
compared with parental JWF2 cells [55]. Conversely, IL-1Ra null mice are more 





suggesting that IL-1 signaling pathway plays a critical role in skin tumor promotion [56]. 
 
In addition to IL-1, cytokines including IL-17, IL-22 and IL-23 are also regarded as 
important inflammatory cytokines for skin tumor promotion [21]. IL-22 and IL-23 bind 
to their receptors IL-10R/IL-22R and IL-12R1/IL-23R, respectively, and 
subsequently activate JAK/STAT3 pathways [57, 58]. Binding of IL-17 to IL-17RC/IL-
17RA leads to activation of TRAF3/6-IKK-IB-NF-B pathway which is often 
dysregulated in skin tumor promotion [21]. Nardinocchi et al. reported that IL-22 and 
IL-17 promotes tumor progression in human melanoma skin cancer and increased 
expression of IL-22 and IL-17 accelerated tumor growth in nude mice injected with 
squamous cell carcinoma cells [59]. IL-23p19 null mice have been shown to be 
resistant to two-stage skin carcinogenesis and IL-17 is highly expressed in the 
hyperplastic skin after TPA treatment in mice [60]. In addition, Wang et al. have 
reported that IL-17 enhanced skin tumor development and disruption of IL-17 
significantly inhibited skin carcinogenesis in mice using skin carcinogenesis protocol 
[61].  
 
Collectively, these data demonstrate that expression of inflammatory cytokines such 
as TNF-, IL-1, IL-1, IL-6, IL-17, IL-22, and IL-23 are elevated during tumor 
promotion and upon binding to their receptors activate oncogenic signaling pathways 
























Cyclooxygenases are enzymes that catalyze the synthesis of prostaglandins from 
arachidonic acid [62]. There are two isoforms of cyclooxygenase, Cox-1 and Cox-2. 
While the expression of Cox-2 is inducible by tumor promoters, Cox-1 is a house 
keeping enzyme that is constitutively expressed in many tissues [62]. Cox-2 has 
been shown to be overexpressed in cancer tissues such as colon, liver, breast, lung, 
pancreas, bladder and stomach [63]. In addition, a number of studies have shown 
that level of Cox-2 is elevated during skin tumor development [64]. Multiple pathways 
are suggested to increase Cox-2 levels by regulating upstream transcription factors. 
Since release of acrachidonic acid from the membrane is induced by PKC activation, 
it is not surprising that TPA-induced PKC activation mediates Cox-2 expression [65-
67]. Also Sp1/Sp3-p38 MAPK activation mediates EGF/EGFR-induced Cox-2 
induction [68]. Several transcription factors including NF-B, CCAAT/enhancer-
binding protein (C/EBP), and upstream stimulatory factors (USFs) directly bind to the 
Cox-2 promoter region [69-71]. Also TPA treatment results in upregulation of Cox-2 
expression in mouse keratinocytes in vitro [64]. Several in vivo studies have shown 
that Cox-2 knock-out mice were less sensitive to two-stage skin carcinogenesis 
when compared to wild-type mice and, topical treatment with selective 
pharmacological Cox-2 inhibitors (e.g., Celecoxib) inhibited skin tumor promotion 
[72-74]. On the other hand, transgenic mice overexpressing Cox-2 in the basal layer 
of the epidermis were more susceptible to two-stage skin carcinogenesis [75, 76]. 
Overall, these data demonstrate that Cox-2 has a clear role as an oncogenic protein 
in skin tumorigenesis and identification and development of safe and effective Cox-2 






NF-B and AP-1 
Nuclear factor κB (NF-κB) and activator protein 1 (AP-1) are important transcription 
factors that are involved the expression of genes related to inflammation, embryonic 
development, proliferation, oncogenesis, and apoptosis [77-79]. Dysregulation of NF-
B is related to anti-apoptosis and proliferation in malignant cells [78]. Stimuli such 
as reactive oxygen species (ROS), lipopolysaccharide (LPS) and cytokines (e.g., 
TNF-, IL-1, and IL-6) have shown to activate NF-B, and many cancer 
chemopreventive agents have inhibitory effects on NF-B activation [79]. NF-B 
consist of p50 and p65 in its resting stage and is inhibited by inhibitory factor IB in 
the cytosol of cells [78]. However, with stimuli such as free radicals, UV and 
cytokines, IB undergoes phosphorylation and ubiquitination for degradation and NF-
B can be activated by phosphorylation. NF-B then translocates into the nucleus 
and binds to B-binding site for activation of numerous genes. AP-1 is a homo- or 
heterodimeric protein consisting of proteins belonging to jun (c-jun, junB, and junD) 
and fos (c-fos, fosB, fra-1, and fra-2) family [80]. Transcription of jun and fos is 
regulated by external stimuli such as UV, growth factors and cytokines, and jun-jun 
or jun-fos dimers bind to AP-1 consensus DNA binding elements in target genes to 
regulate expression [77, 80, 81].  
 
A considerable number of studies have shown that NF-B and AP-1 play an 
important role in the development of skin tumors in the two-stage model. For 
example, AP-1 potentially promotes skin cancer development via its control of 
keratinocyte survival and differentiation [82]. Young et al. reported that transgenic 





promoter exhibited dramatic inhibition of papilloma induction in the two-stage skin 
carcinogenesis protocol [83]. Expression of NF-B p50 and DNA binding activity of 
NF-B p65/p50 are increased in mouse skin papillomas and squamous cell 
carcinomas [84]. In addition, Kim et al. have shown that mice with keratinocyte-
restricted p65/RelA deficiency have reduced sensitivity to two-stage skin 
carcinogenesis by protecting keratinocytes from DNA damage-induced death and 




Signal transducer and activator of transcription 3 (STAT3) is one of six mammalian 
STAT family members that have been identified [86, 87]. STAT3 can be activated 
through cytokine receptors (e.g., IL-6, IFN), G-protein coupled receptors, growth 
factor receptors (e.g., EGFR), or non-receptor tyrosine kinase (e.g., c-src) [29, 86, 
87]. Once activated, STAT3 will homodimerize and then translocate to the nucleus 
where it will bind to DNA and activate transcription of genes involved in regulation of 
anti-apoptosis, cell proliferation, survival, and angiogenesis [29].  
 
The role of STAT3 in epithelial carcinogenesis has been well studied [29, 87]. 
Activated STAT3 in epidermis by chemical tumor promoters or UVB regulates the 
expression of target genes such as c-myc, Bcl-xL, survivin, Bcl-2, cyclin D1, c-Myc, 
c-fos, VEGF, and twist that are involved in stem cell maintenance, survival, 
proliferation and EMT [29, 86, 87]. Several studies have shown that STAT3 is 
important for skin tumor promotion, and ablation of STAT3 leads to reduction in 





expression of genes involved in regulation of cell cycle (e.g., cyclin D1 and c-myc) in 
chemically-induced skin carcinogenesis [86, 88-93]. Conversely, transgenic mice 
expressing a constitutively active form of STAT3 in the epidermis displayed 
increased malignant progression during two-stage carcinogenesis [92]. In this study, 
the transgenic mice developed skin tumors more rapidly and with higher number of 
tumors when compared to WT mice. Furthermore these tumors became squamous 
cell carcinomas bypassing the premalignant stage of skin carcinogenesis. Overall, 
these data suggest that STAT3 plays an important role in epithelial carcinogenesis 
and given the strong evidence for STAT3 involvement in all stage of tumorigeneis, it 
represents an attractive target protein for cancer chemoprevention.   
 
AMPK 
The 5′-AMP-activated protein kinase (AMPK) is an energy sensing enzyme that 
contains α-, β-, and γ-subunits and once activated, AMPK phosphorylates and 
regulates key enzymes to regulate cellular lipid and protein metabolism in response 
to stimuli such as exercise and changes in cellular ADP/ATP ratio [94-96]. It is 
activated primarily by two molecules, tumor suppressor LKB1 and Ca+2/calmodulin-
dependent protein kinase  (CaMKK) [97-99]. The reduced ratio of ADP/ATP leads 
to LKB1 activation, which results in phosphorylation of AMPK- on threonine 172 [94, 
98, 99]. Also increases in intracellular Ca+2 level can activate CaMKK kinase activity 
which leads to activate phosphorylation and activation of AMPK-[99]. Emerging 
evidence indicates that AMPK is a promising metabolic tumor suppressor and a 
target for cancer prevention and therapy. The AMPK pathway is negatively correlated 





autophagic signaling pathway through Ulk1. In addition, AMPK signaling also 
interacts with two critical tumor suppressors, p53 and ATM to coordinate metabolic 
checkpoints and DNA repair response [100, 101]. Canto et al. showed that AMPK 
activation increases intracellular NAD+ and subsequently stimulates SirT1 activity 
[102, 103]. Interestingly, Lan et al. have reported that SirT1 can act as an upstream 
activator of LKB1 by showing that SirT1 deacetylates LKB1 kinase which 
subsequently increased its activity [104]. Since LKB1 is an upstream kinase of AMPK, 
the SirT1-LKB1 pathway increased AMPK activation [104]. These data suggest that 
there might be a positive feedback loop between AMPK and SirT1 for potentiation of 
their activation to control energy balance effectively. Even though limited information 
is available for the role of AMPK as a tumor suppressor, Wu et al. reported that 
AMPK activation is decreased in human and UVB-induced mouse squamous cell 
carcinoma when compared to normal skin [105]. Also, in this study, topical treatment 
with AMPK- activator, AICAR and metformin, reduced UVB-induced skin 
tumorigenesis. More recently, our group reported that metformin, which is known to 
activate AMPK-significantly inhibited skin tumor promotion by TPA when given in 
drinking water [11]. Furthermore, topical treatment of resveratrol, a calorie restriction 
mimetic and SirT1 activator, suppressed skin tumorigenesis [106-108]. Overall, these 
data suggest that AMPK might act as a tumor suppressor and identification and 
development of safe AMPK activators might be a good novel strategy for cancer 
prevention.  
 
1.3 Calorie restriction and skin tumorigenesis 
Calorie restriction (CR) is a reduction in calorie intake (usually in the range of 





the most consistent non-pharmacological factor that increases lifespan and 
decreases detrimental biological functions in model organisms [109]. Recently, 
numerous studies have shown that CR inhibits tumorigenesis in various 
experimental models [110-119]. A number of studies reported that CR suppresses 
tumor promotion, however, no effects were observed on either initiation or 
progression using the well-established two-stage skin carcinogenesis model [113, 
120, 121]. Proposed mechanisms for the inhibitory effect of CR on skin tumor 
promotion are as follows: i) 10~40% CR (low fat or low carbohydrates) inhibits TPA-
induced tumor promotion due to reduced PKC activity in epidermal cells [112, 113]; ii) 
40 % CR blocks TPA-induced AP-1 and ERK1/2 activation in skin tumor promotion 
[122]; iii) 30 % CR decreases TPA-activated epidermal signaling of EGFR & IGF-1R 
and their crosstalk as well as PI3K/Akt/mTOR signaling in mouse epidermis [40, 121, 
123]; iv) CR has anti-tumor promoting effect and the effect, at least in part, is 
mediated through an Nrf2- mechanism [124, 125]. 
 
CR delays the onset of aging-related chronic disease including tumorigenesis as 
mentioned above. Even though CR has been shown to benefit human health, it is 
extremely difficult to maintain a life style based on 20~40% CR for a large portion of 
the population. Therefore, it is not surprising that considerable effort has been placed 
on developing CR mimetics by focusing on identification of pathways that regulate 
the beneficial effects of CR without commitment of major lifestyle changes.   
 
1.4 Perilla (P.) frutescens 
P. frutescent belongs to the annual mint family and is an edible plant (Figure 1-4) 





pleasant flavor and taste, it is widely used in Korean food ingredients. For example, 
perilla leaves can be added to fish, rice, soup, and vegetables, and it can be pickled 
for many dishes. P. frutescens is not only used as a food ingredient but also for 
medicinal preparations due to its anti-allergic and anti-inflammatory effect. Banno et 
al. have reported that a number of pentacylic triterepenes are present in P. 
frutescens including ursolic acid (UA), oleanolic acid (OA), corosolic acid (CA), 3-epi-
corosolic acid (3-epiCA), maslinic acid (MA), 3-epimaslinic acid (3-epiMA), tormentic 
acid (TA), pomolic aicd (PA), hyptadienic acid (HA), and augustic acid (AA) (Figure 1-
5) [126]. These compounds are triterpenoid carboxylic acids with the molecular 
formula C30H48 having six isoprene units and are synthesized in P. frutescent by 
cyclization of squalene. Banno et al. [126] reported that all of these compounds 
exhibited some anti-inflammatory activity against TPA-induced ear edema. Also TA 
was shown to inhibit skin tumor promotion by 12-O-tetra-deacnoylphorbol-13-acetate 
(TPA) in this study [126]. In other studies both UA and OA have been shown to inhibit 
skin tumor promotion by TPA [107, 127, 128]. Even though several of the compounds 
found in P. frutescens have been shown to possess anti-tumor promoting and cancer 
chemopreventive activity, only limited information is available on the other triterpenes 









Figure 1-4. Perilla (P.) frutescens 
P. frutescent var. crispa (Labiatae) belongs to the annual mint family. It is edible and 
is used as a medicinal plant in many Asian countries. There are two chemo-types: 
red perilla and green perilla. The photo is of green perilla.  






Figure 1-5. Pentacyclic triterpenes found in P. frutescens 
1, Ursolic acid; 2, Corosolic acid; 3,3-epi-corosolic acid;4, Pomolic acid; 5, Tormentic 
acid; 6, Hyptadienic acid; 7, Oleanolic acid; 8, Augustic acid; and 9, 3-epi-maslinic 
acid 
      Adapted from Bioscience, Biotechnology, and Biochemistry [126]:  Banno, N., et al., 
Triterpene acids from the leaves of Perilla frutescens and their anti-inflammatory and 














1.4.1 UA and related triterpenes found in P. frutescens 
UA is a natural pentacyclic triterpenoid carboxylic acid found in P. frutescen 
(Japanese basil) as well as rosemary, apples, elder flowers, and many other plants. 
It has been reported to have a broad range of pharmacological properties and is 
regarded as one of most potent chemopreventive agents for cancer. UA has been 
shown to have apoptotic, anti-inflammatory and anti-tumorigenic effects in various 
cancer models including prostate, ovary, small intestine, stomach, and skin [126, 127, 
129]. Further studies have revealed that UA has a broad-spectrum of anti-
carcinogenic effects including prevention of DNA damage, inhibition of EGFR/MAPK 
signaling, inhibition of angiogenesis, activation of apoptotic signaling pathways, and 
inhibition of Akt-mTOR, NF-B, Cox-2, and STAT3 signaling pathways [129, 130]. 
Although several studies have reported that UA inhibited TPA-induced inflammation, 
hyperplasia and tumor promotion in mouse skin [107, 126, 127], its inhibitory 
mechanism is not fully understood. Recently, several studies reported that UA also 
has an anti-obesity effect and mimics some of the effects of CR by modulating 
Akt/mTOR signaling pathways [131-133]. UA has also been shown to activate the  
LKB1/AMPK pathway for inhibition of adipogenesis [134].  
 
Together with UA, OA is also found in P. frutescens. It is also abundant in ginseng 
root and olive oil. UA and OA are often found together in plants and possess similar 
pharmacological properties [129, 135-137]. OA exhibits unique properties including 
anti-inflammatory, gastro-protective, wound-healing, and anti-microbial effects [138, 
139]. In addition, several studies have shown anti-cancer effects of OA in both in 
vitro and in vivo studies [127, 140]. For example, OA inhibits proliferation and 





144]. It has been shown to have antioxidant capacity by activating Keap1-Nrf2-ARE 
pathways in hepatocellular cancer cells [145]. Two, 5, and 10 mol of OA 
pretreatment inhibited TPA-induced expression of ornithine decarboxylase, c-fos, 
and c-Jun [140] and 41 nmol of OA given as a pretreatment inhibited TPA promotion 
in the two stage skin carcinogenesis assay [127]. In another study, OA inhibited 
growth of hepatocellular carcinoma cells by inducing p53-ERK-mediated cell cycle 
arrest and mitochontrial-dependent apoptosis in BALB/C mice [146]. Furtado et al. 
reported OA inhibited 1,2-dimethyhydrazine induced colon carcinoma in rats [147].  
 
Maslinic acid (MA), also known as crategolic acid, has been isolated from P. 
frutescens as well as other edible plants such as olive fruit, spinach, eggplant, 
mustard, basil and legumes [148]. A number of in vitro studies have shown MA to 
possess anti-proliferative, apoptotic, and anti-cancer properties. The anti-proliferative 
and apoptotic properties of MA have been demonstrated in various cancer cell lines 
such as colon, liver, bladder, uterus and breast [149-154]. Proposed mechanisms for 
the anti-cancer effect of MA in in vitro experiments include activation of caspase-3, 
inhibition of Cox-2 expression, suppression of IB-NF-B pathway, increased 
expression of p53, and modulation of JNK1/2 or p38 pathway [148]. Until now, only a 
few studies have reported the anti-tumor activity of MA using in vivo models. Li et al. 
have demonstrated subcutaneous administration of MA (10 and 50 mg/kg) inhibited 
growth of pancreatic cancer cells in a xenograft mouse model via an increase of 
apoptosis and reduction of NF-B-mediated anti-apoptotic genes, including survivin 
and Bcl-xL [155]. In another study, dietary MA (100 mg/kg of control diet) in APC 
Min/+ mice reduced colon carcinogenesis by 45 % [156]. In addition, MA inhibited 





CA exists in abundance in the plant kingdom including bananas, loquat, and P. 
frutescens. A number of studies have shown that it has anti-diabetic, anti-oxidant, 
anti-inflammatory, apoptotic, and anti-cancer activities [157-164]. The anti-cancer 
effects of CA have not been extensively studied in vivo. However, several in vitro 
studies have been reported growth inhibitory effects in many cancer cell lines 
including gastric, colon, cervix, leukemic and lung [157-163]. Suggested 
mechanisms for its anti-cancer effects include inhibition of PKC activity [157], 
induction of cell cycle arrest, activation of apoptotic molecules (e.g., Bax and 
caspases, 3,8, and 9) [158, 161], regulation of cell cycle proteins (e.g., induction of 
p27 and inhibition of cyclin D1) [159], deregulation of HER2 downstream pathways 
(e.g., reduction of activated Erk or Akt ) [159], modulation of the AMPK-mTOR 
pathway [160], inhibition of NF-B and STAT3 pathway [162], and downregulation of 
-catenin [163].  
 
In summary, previous data have demonstrated that UA is an effective 
chemopreventive agent in animal models. Together with UA, a number of pentacyclic 
triterpenes found in P. frutescens, including, OA, CA, MA appear to also possess 
anti-carcinogenic properties. However, the mechanisms of their chemopreventive 
activities are poorly understood and several of the triterpenes found in P. frutescens 
including, AA, 3-epiCA, and 3-epiMA have not been thoroughly studied. In this regard, 
detailed examination of anti-carcinogenic effect of these compounds is needed. In 
addition, more information on the exact inhibitory mechanism(s) for this class of 







1.5 Resveratrol  
Resveratrol (Res) is a phytoalexin which possess antimicrobial and antioxidant 
properties [165, 166]. Res is synthesized de novo by plants to counteract pathogen 
infections. It is found in plants such as in grapes, berries, and peanuts. For the past 
several decades, Res has been extensively studied and shown to have 
cardiovascular benefit (French paradox), CR-resembling effects, anti-diabetic effects, 
and anti-cancer effects in mice and humans. In addition, Res is regarded as an 
effective chemopreventive agent based on numerous preclinical studies [106-108, 
167-172]. Res has been shown to inhibit skin tumor promotion and inhibit the growth 
of many cancer cell lines, including breast, prostate, colon and liver. Several studies 
have elucidated potential mechanisms for its anti-tumor promoting effects including 
inhibition of Cox-2, NF-B, and mTOR signaling pathways in skin [167, 169]. Several 
reports suggest that Res mimics some of the effects of CR on life span in worms and 
other model organisms, especially by inhibiting inflammation and mTOR [170, 173]. 
Res also mimics the effects of CR by increasing SirT1 and AMPK activation [171]. 
Also Boily et al. have suggested that the anti-promoting effect of Res on mouse skin 
is mediated, at least in part by SirT1 [106]. Although the anti-cancer effects of Res 
observed both in vitro and in vivo is widely studied, the exact mechanism of its anti-
proliferative effects remains to be elucidated.  
 
1.3 Combination of phytochemicals and chemoprevention 
Emerging evidence suggests that combinations of phytochemicals may be a good 
strategy to achieve greater chemopreventive efficacy [174, 175]. Many 
phytochemicals appear to have CR mimetic properties (e.g., resveratrol [171]).  





toxicity when compared with synthetic compounds, combining phytochemicals may 
be an advantage for cancer prevention. Several studies have shown that 
combinations of natural compounds can produce potentially synergistic inhibitory 
effects on tumor formation (e.g., resveratrol + grape seed extract and ellagic acid + 
grape seed extract) [176-181]. Thus, combining agents may provide the most 
rational and effective approach to cancer chemoprevention and provide overall 
effects that more similarly mimic CR.  
 
1.7 Hypothesis and specific aims 
The overall goal of this study was to examine the effect of natural compounds that 
mimic some effects of CR on skin tumor promotion. In particular, we tested the 
possible CR effects of 7 different triterpenes found in P. frutescens on TPA-induced 
skin tumor promotion. Preliminary data showed that an extract from green perilla 
leaves inhibited TPA-induced Akt, NF-B p65, p70S6K, Cox-2, and CDK2. Also the 
perilla extract partially reversed TPA effect on PDCD4. Based on these preliminary 
data a series of related pentacyclic triterpenes, including UA from P. frutescens, were 
analyzed. These components were evaluated for their inhibitory effects on TPA-
induced epidermal signaling pathways, hyperproliferation, inflammation and skin 
tumor promotion. Moreover, we also focused on the effects of combined treatment of 
one of the pentacyclic triterpenes, UA, and Res on TPA-induced skin tumor 
promotion. Preliminary data had indicated that combining these two agents could 
produce a greater CR mimetic effect. The hypothesis to be tested was that 
triterpenes found in P. frutescens possess CR mimetic properties in their 
ability to inhibit mouse skin tumor promotion. Furthermore, UA in combination 





range of growth factor, inflammatory and possibly other signaling pathways 
similar to CR to suppress proliferation of initiated keratinocytes and inhibit 
skin tumor promotion. 
 
The specific aims are as follows: 
 
Specific aim 1: Examine the effect of UA and a series of related pentacyclic 
triterpenes on epidermal signaling pathways by TPA. 
In this aim, a series of pentacyclic triterpenes including UA, OA, AA, CA, 3-epiCA, 
maslinic acid, and 3-epiMA found in P. frustescens were examined for their effects on 
TPA-induced epidermal signaling pathways important for skin tumor promotion.  
The pathways analyzed included RTKs (EGFR and IGF1R) Akt/mTORC1, NF-B, 
AP-1, p38, JNK1/2, and AMPK. 
 
Specific aim 2: Examine the effect of UA and a series of related triterpenes on 
keratinocyte proliferation and skin inflammation in relation to their ability to 
inhibit skin tumor promotion by TPA.  
In this aim, we examined the effect of UA and other triterpenes on TPA-induced 
epidermal hyperplasia, and hyperproliferation. We also examined the effect of these 
compounds on TPA-induced skin inflammation and inflammatory gene expression. In 
this Specific Aim, we also evaluated the ability of these triterpenes from P. frutescens 
(except AA) to inhibit skin tumor promotion by TPA during two-stage skin 
carcinogenesis.  
 





given together with Res on TPA-induced epidermal signaling pathways, 
epidermal hyperproliferation, inflammation and skin tumor promotion. 
In this Specific Aim, we evaluated the effects of combined treatment with UA + Res 
on epidermal signaling pathways, epidermal proliferation, skin inflammation and 
inflammatory gene expression induced by TPA compared to either compound given 
alone. Furthermore, we tested the ability of this combination to produce a 










Chapter 2. Materials and Methods 
Animals and Diets 
Female Hsd : ICR (CD-1) and FVB/N mice 6-7 weeks of age were purchased from 
Harlan Laboratories Inc. (Frederick, MD) and the National Cancer Institute (Frederick, 
MD), respectively. Mice were group housed for all experiments. For the short-term 
experiments, mice were fed a regular chow diet. For tumor experiments, mice 
received either an overweight control diet (D12450B, 10 Kcal% fat; Research Diets 
Inc.) or an obesity inducing diet (D12492, 60 Kcal % fat; Research Diets Inc) (see 
diet formulas in Table 2-1).  
 







UA and OA were purchased from Sabinsa Corporation and Standford Chemicals, 
respectively. AA, CA, MA, 3-epiCA, and 3-epiMA were prepared as recently 
described by us [211]. All triterpenes used in the current experiments were > 98% 
pure. We received Res from Orchid Chemicals & Pharmaceuticals Ltd. DMBA was 
purchased from Sigma Chemical Co. and TPA was purchased from LC laboratories. 
 
Short-term treatment protocol for the anti-tumor promoting effect of a series of 
related pentacyclic triterpenes 
Mice were treated using a short-term treatment protocol involving 4 applications of 
TPA. For this protocol, as shown in Figure 2-1, groups of mice (7-8 weeks of age) 
were shaved on the dorsal skin and then two days later treated twice weekly for two 
weeks with 0.2 ml acetone vehicle, 2 mol of UA, OA, AA, CA, 3-epi-CA, MA, and 3-
epi-MA 30 min prior to each 6.8 nmol of TPA treatment. Mice were then sacrificed at 
various times thereafter for collection of epidermal tissue. 
 
Short-term treatment protocol for the anti-tumor promoting effect of the 
combination of UA + Res 
For a number of experiments, mice were treated using a similar short-term treatment 
protocol involving 4 applications of TPA (Figure 2-2). For these experiments, groups 
of female ICR mice (7-8 weeks of age) were shaved on the dorsal skin and then two 
days later treated twice-weekly for two weeks with 0.2 ml acetone vehicle, UA (2 
μmol) or Res (2 μmol) 15 min prior to each 6.8 nmol of TPA treatment. For the 
combination, mice received UA (2 μmol) and Res (2 μmol) 15 min and 30 min prior to 





collection of epidermal tissue.  
A 
Group Pretreatment (-30min) Treatment 
1 Acetone Acetone 
2 Acetone 6.8 mol TPA 
3 2 mol UA 6.8 mol TPA 
4 2 mol OA 6.8 mol TPA 
5 2 mol AA 6.8 mol TPA 
6 2 mol CA 6.8 mol TPA 
7 2 mol 3-epiCA 6.8 mol TPA 
8 2 mol MA 6.8 mol TPA 
9 2 mol 3-epiMA 6.8 mol TPA 
 
B 
Figure 2-1. Short-term treatment protocol for the anti-tumor promoting effect of 
a series of related pentacyclic triterpenes 








Group 1st Pretreatment (-30min) 2nd Pretreatment (-15min) TPA Treatment 
1 Acetone Acetone Acetone 
2 Acetone Acetone 6.8 mol TPA 
3 Acetone 2 mol UA 6.8 mol TPA 
4 Acetone 2 mol Res 6.8 mol TPA 




Figure 2-2 Short-term treatment protocol for the anti-tumor promoting effect of 
combination of a UA + Res 







Two-stage skin carcinogenesis assays for the anti-tumor promoting effect of 
pentacyclic triterepens found in P. frutescens  
Female ICR mice (n=30/group) 7-8 weeks of age maintained on 10 Kcal % fat diet 
(overweight diet) were shaved on the dorsal skin and then 48 hrs later initiated with a 
single topical application of 25 nmol of DMBA in 0.2 ml acetone or acetone vehicle. 
During tumor promotion, mice received 2 μmol of UA , OA, CA, Epi-CA, MA or Epi-
MA 30 min prior to each 6.8 nmol TPA application. TPA was administered twice-
weekly for the duration of the experiment (i.e., 23 weeks (Figure 2-3A). Body weight, 
tumor incidence (percentage of mice with papillomas) and tumor multiplicity (average 
number of papillomas per mouse) were measured once a week for the duration of 
the experiment (Figure 2-3A). In addition, the surface area of all detectable 
papillomas was measured by digital calipers at the termination of the experiment. 
 
Two-stage skin carcinogenesis assays for the anti-tumor promoting effect of a 
combination of UA + Res  
As shown in Figure 2-3B, Female ICR mice (n=30/group) 7-8 weeks of age were 
shaved on the dorsal skin and then 48 hrs later initiated with a single topical 
application of 25 nmol of DMBA in 0.2 ml acetone or acetone vehicle . Two weeks 
after initiation, mice were randomized to receive one of the two experimental diets 
(overweight control diet and obesity-inducing diet) for 6 weeks before starting 
treatment with the tumor promoter, TPA. During tumor promotion, mice received 2 
μmol of UA and 2 μmol of Res 15 min prior to each TPA application. For the 
combination, Res was given 30 min and UA was given 15 min prior to each 6.8 nmol 
dose of TPA. TPA was administered twice-weekly for the duration of the experiment 





and tumor multiplicity (average number of papillomas per mouse) were measured 
once a week for the duration of the experiment. In addition, the surface area of all 




































Figure 2-3. Two stage carcinogenesis assays 
A, Two-stage skin carcinogenesis for the effect of UA and other triterpenes found in P. 
frutescens on skin tumor promotion by TPA. B, Two-stage carcinogenesis assay for 





Label retaining cell (LRC) assay 
For these experiments, 10-day old mice were injected with BrdU [50 μg/g body 
weight (B.W.)] i.p. every 12 hrs over 2 days. Seventy days later, mice were shaved 
on the dorsal skin and then treated twice weekly for two weeks (4 treatments total) 
with 0.2 ml acetone vehicle, UA (2 μmol) or Res (2 μmol) 15 min prior to each 6.8 
nmol of TPA treatment. For the combination, mice received UA (2 μmol) and Res (2 
μmol) 15 min and 30 min prior to TPA treatment, respectively. Mice were sacrificed 
48 hrs after the last treatment and dorsal skin samples were fixed in 10% neutral-
buffered formalin for 48 hrs. The fixed dorsal skin samples were embedded in 
paraffin and then sectioned for staining with anti-BrdUrd antibody (Abcam). LRCs 
(BrdUrd positive cells) in bulge region of each hair follicle were quantitated as 
previously described [182].   
 
Histological analyses 
For analysis of epidermal thickness and labeling index (LI) as well as the number of 
infiltrated inflammatory cells, mice received short-term protocol regimen. BrdUrd 
(100 μg/g B.W.) in PBS was injected i.p. to mice 30 min prior to sacrifice. Mice were 
sacrificed 48 hrs after the last TPA treatment and dorsal skin was excised and fixed 
in 10% neutral-buffered formalin. The fixed skin samples were embedded in paraffin, 
sectioned (4 μm) and stained with hematoxylin & eosin (H & E), toluidine blue O, 
anti-BrdUrd, CD3, or CD45. Epidermal thickness and LI were determined as 
described previously [183]. Inflammatory cell infiltration was determined by counting 







Preparation of epidermal protein lysates, cytosolic fractions, nuclear fractions 
and RNA 
Mice received pretreatment with acetone or compounds before TPA treatment 
according to the short-term treatment protocol. Mice were sacrificed 6 hrs after the 
last TPA treatment. After sacrifice, epidermal protein lysates were collected as 
previously described [10]. Briefly, the epidermis was removed by scraping with a 
razor blade and then homogenized in radioimmunoprecipitation assay (RIPA) lysis 
buffer (50mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl, 1 mmol/L EDTA, 1mmol/L 
sodium orthovanadate, 1% NP-40, phosphatase inhibitor cocktail 1 and 2, and 
proteinase inhibitor cocktail) on ice. Lysates were centrifuged at 14,000 rpm for 15 
min at 4 ºC. Supernatants were quantitated for protein amount and then subjected to 
Western analyses. 
For electrophoretic mobility shift assays (EMSAs), the epidermal cytosolic and 
nuclear fractions were isolated using NE-PER nuclear and cytoplasmic 
extraction reagents (Thermo Scientific Inc). The protein lysates and nuclear/cytosolic 
fractions were used immediately or stored at -80 ºC until used. Epidermal RNA 
samples were isolated as previously described [184, 185] and subjected for 
quantitative real-time PCR (qPCR) analysis.  
 
Western blot analysis 
For Western blot analysis, the protein concentration of the supernatant was 
measured by using the protein lowry assay kit (Thermo Scientific). Aliquots of 
supernatant containing 30 g protein were boiled in sodium dodecylsulfate (SDS) 
sample loading buffer for 5 min before electrophoresis on 6-15 % SDS-





were blocked with 5% bovine serum albumin (BSA) or 5% non-fat dry milk-TBST 
buffer [TBS containing 0.1% Tween-20] for 1 hr at room temperature. The 
membranes were incubated for overnight at 4℃ with 1: 1000 dilutions of primary 
antibodies. Blots were washed three times with TBST at the 10 min interval followed 
by incubation with 1: 5000 horseradish peroxidase-conjugated secondary antibodies 
(rabbit or mouse) for 1 hr and washed in TBST for three times.  The transferred 
proteins were visualized with an ECL detection kit according to the manufacturer‟s 
instructions.  
Antibodies against the following proteins were used: p-NF-B p65S536, IGFR-1R, 
STAT3, p-STAT3S727, p-STAT3Y705, p-AktS308, Akt, p-p38T180/Y182, p38, p-
JNK1/2T183/Y185, JNK1/2, p-c-JunS73, c-Jun, Fas, PDCD4, p-AMPK-, AMPK-, 
SirT1, p-LKB1S416, p-mTORS2448, mTOR, p-rS6S240/244, rS6, p-Ulk1S555, Ulk1, ATG5, 
LC3IIB, beclin, and -tubulin (Cell Signaling Technology); p-EGFRY1086 (Abcam); 
EGFR (Millipore); p21 and lamin A/C (Santa Cruz Biotechnology); p27 (BD 
Biosciences); actin and twist1 (Sigma). 
  
EMSA 
EMSA was performed using a DNA-protein binding detection kit according to the 
manufacturer‟s protocol (Thermo Scientific Inc.). Briefly, AP-1 oligonucleotide probe 
(5'-Biotin-CGC TTG ATG ACT CAG CCG GAA-3'), NF-B oligonucleotide probe (5'-
Biotin-AGT TGA GGG GAC TTT CCC AGG C-3'), and Egr-1 oligonucleotide probe 
(5'-Biotin-GGA TCC AGC GGG GGC GAG CGG GGG CCA-3') were labeled with 
biotin at the 5‟ end. Ten μg of nuclear protein was incubated with either DNA oligos 





Optimization and Control Kit (Thermo Scientific Inc). Biotin-labeled DNA-protein 
complexes were run on 5 % polyacrylamide gel for 1 hr at 100 V and transferred on 
nylon membranes for 30 min at 100 V using wet transfer modules. DNA-proteins 
complexes were then detected using the Chemiluminescent Nucleic Acid Detection 
Module (Thermo Scientific Inc.).  
 
qPCR analysis 
qPCR analyses were performed as previously described [186]. Briefly, cDNA was 
generated from epidermal RNA samples in a reaction (total volume of 13 μl) 
containing 1 μg of RNA, 2-3 µl random primers (50 ng/μl), 1 µl 10 mM dNTP mix 
(Invitrogen), and RNase-free water. For primer annealing, the mixtures were heated 
to 65 °C for 5 min and incubated on ice for 1 min. Subsequently, 4 µl 5X First-Strand 
buffer (Invitrogen), 1 μl 0.1 M DTT, and 1 μl SuperScriptTM III reverse transcriptase 
(Invitrogen) were added to the mixtures and incubated at 25 °C for 5 min. For primer 
extension, the mixture was incubated at 50 °C for 50 min and then at 75 °C for 15 
min to inactivate. For qPCR, cDNA (150 ng) was mixed with 2X TaqMan gene 
expression master mix (AB Applied Biosciences), 20X primer sets (IL-1, IL-1, IL-
22, ribosomal 18 S), and nuclease-free water in a total volume of 10 μl. For qPCR of 
Cox-2 mRNA, 2X iTagTM universal SYBR○R  green supermix (Bio-rad), 1 μM primers 
(Cox-2, and GAPDH) nuclease-free water were added to cDNA (150 ng). The 
mixtures were then subjected to qPCR using ViiATM 7 real time instrument and 








For comparisons of quantitative protein expression, gene expression, epidermal 
thickness, labeling index, the number of infiltrated inflammatory cells, transcriptional 
activities and tumor multiplicity and tumor size, the Mann-Whitney U test was used. A 
one-tailed Fisher‟s exact test and Mantel-Cox test was used for comparisons of 
tumor incidence and tumor latency, respectively. Significance in all cases was set at 























Chapter 3. Evaluation of pentacyclic triterpenes found in Perilla frutescens for 
inhibition of skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate.  
3.1 Introduction 
According to the American Cancer Society, there will be an estimated 1,658,370 new 
cancer cases diagnosed and 588,430 cancer deaths in the US in 2015. In addition, 
cancer remains the second most common cause of death in the US, accounting for nearly 
1 of every 4 deaths [1]. In the mid-1970s, Michael Sporn created the term 
„chemoprevention‟, which is defined as the use of natural or synthetic agents to reverse, 
inhibit or slow the process of carcinogenesis [187]. Chemoprevention may involve 
interruption of the multi-stage carcinogenesis process during tumor initiation, promotion, 
and/or progression [6]. Various tumor models have been used to evaluate cancer 
preventive agents. The multi-stage skin carcinogenesis model is a well-established model 
of epithelial carcinogenesis with distinct and definable stages of tumor development [13, 
14]. This model can be used to evaluate cancer chemopreventive agents on each 
individual stage of the carcinogenesis process and is particularly useful for identifying 
potential mechanisms of chemopreventive action.  
 
Perilla frutescens (P. frutescens) belongs to the annual mint family and is an edible plant 
frequently used in Asian countries including Korea, Japan and China. It has a pleasant 
flavor and taste and is used as a food ingredient. For example, perilla leaves can be 
added to fish, rice, soup, and vegetables and also it can be pickled for many dishes. The 
perilla leaf extract contains a number of constituents that have pharmacologic activity, 
such as triterpenoids, rosmarinic acid, luteolin, caffeic acid, epigenin, and beta-carotene 
[126, 188, 189]. These compounds have various biological activities reported such as 





emerging evidence has shown perilla extract has anti-inflammatory [126, 189, 195] and 
anti-cancer effects [188, 194, 196, 197].  
 
Ursolic acid (UA) is a natural pentacyclic triterpene compound present in various edible 
plants including P. fructescens [128, 129, 136, 137, 154]. It has potent cancer 
chemopreventive activity and possesses a wide range of pharmacological activities. UA is 
widely studied for its apoptotic, anti-inflammatory, and anti-tumorigenic properties, 
including the ability to inhibit skin tumor promotion in the mouse skin model [107, 108, 126, 
127, 129]. A number of mechanisms have been attributed to the ability of UA to inhibit 
tumor development in these various model systems. UA has been shown to suppress 
multiple cell signaling pathways including, growth factor receptor activation (e.g., EGFR), 
and signaling through IKK/NF-BAkt/mTOR, Cox-2, STAT3, MMP9, and VEGF [129, 130, 
137]. In addition, UA has been shown to alter levels of Bax and caspases and increase 
the activation of tumor suppressor proteins such as p53 and AMPK [137, 198].  
 
In addition to UA, a number of other pentacylic triterpenes including, oleanolic acid (OA), 
corosolic acid (CA), 3-epi-corosolic acid (3-epiCA), maslinic acid (MA), 3-epi-maslinic acid 
(3-epiMA), tormentic acid (TA), pomolic aicd (PA), hyptadienic acid (HA), and augustic 
acid (AA) are found in P. frutescens [126]. These compounds are triterpenoid carboxylic 
acids with molecular formula C30H48 having six isoprene units and are synthesized in P. 
frutescens by cyclization of squalene. Banno et al., have reported that all of these 
compounds exhibited anti-inflammatory effects against TPA-induced ear edema [126]. 
They also have shown that UA, CA, 3-epiCA, TA, and 3-epiMA have potent inhibitory 
effects on TPA-induced Epstein-Barr virus early antigen activation [126]. Of the 





for inhibition of skin tumor promotion by TPA [107, 108, 126, 127].  
 
In the current study, we examined the effect of 7 different triterpenes including, UA, OA, 
AA, CA, 3-epiCA, MA, and 3-epiMA present in P. frutescens on epidermal proliferation, 
skin inflammation, inflammatory gene expression and epidermal signaling pathways 
induced by TPA. Six of these compounds were also evaluated for their ability to inhibit 
skin tumor promotion by TPA. Several of the compounds, especially 3-epiCA and MA, 
were found to be more effective for inhibition of skin tumor promotion than UA and are 
considered excellent candidates for further study of their chemopreventive effectiveness 










































3.2.1 Effect of pentacyclic triterpenes found in P. frutescens on skin tumor 
promotion by TPA.  
To evaluate the anti-tumor promoting effect of UA and related triterpenes (i.e., OA, 
CA, 3-epiCA, MA, and 3-epiMA) present in P. frutescens, a two-stage skin 
carcinogenesis experiment was conducted using female ICR mice. AA was not 
included in the tumor experiment due to insufficient amount of this compound for 
evaluation. The control group in this experiment that was initiated with DMBA and 
promoted with TPA had 10.57 papillomas per mouse (see Figure 3-1A and Table 3-1). 
All of the pentacylic triterpenes evaluated in this experiment significantly inhibited 
skin tumor promotion by TPA. Pretreatment with UA resulted in a 42% inhibition of 
papilloma formation (6.17 papillomas per mouse; p<0.05, Mann-Whitney U test) 
(Table 3-1). OA (35% inhibition; 6.87 papillomas per mouse) and 3-epiMA (37% 
inhibition; 6.7 papillomas per mouse) also significantly inhibited skin tumor promotion 
by TPA (p<0.05; Mann-Whitney U test), however, these two compounds were not 
more effective that UA (p>0.05, Mann-Whitney U test). Of the remaining compounds 
evaluated, CA inhibited TPA promotion by 49% (5.38 papillomas per mouse; p<0.05, 
Mann-Whitney U test) when compared to TPA-only group but this was not 
significantly different compared to the group pretreated with UA. On the other hand, 
both 3-epiCA and MA inhibited skin tumor promotion by TPA to a greater extent than 
UA. In this regard, mice pretreated with 3-epiCA and MA exhibited 4.33 and 3.73 
papillomas per mouse, respectively giving a 59% and 65% inhibition in tumor 
multiplicity (p<0.05; Mann-Whitney U test compared to the TPA only group and the 






As shown in Figure 3-1B, the incidence of papillomas in the group treated with TPA 
only was 97 % at week 25 (Figure 3-1B and Table 3-1). Pretreatment with UA, OA, 
CA and 3-epiMA did not significantly reduce the overall incidence of papillomas 
compared to the TPA-only treated group (p>0.05, Fisher‟s exact test). However, 
pretreatment with 3-epiCA and MA significantly reduced the overall tumor incidence 
(67% and 73%, respectively) when compared to TPA only group or the UA-
pretreated group (both 97% incidence). These reductions in tumor incidence with 3-
epiCA and MA were statistically significant (p<0.05, Fisher‟s exact test). 
 
As shown in Figure 3-1C, tumor latency was also significantly affected by 
pretreatment with the various triterpenes. In this regard, pretreatment with UA, OA, 
CA, 3-epiCA, 3epiMA and MA significantly delayed tumor development when 
compared to TPA-only treated group (p<0.05; Mantel-Cox test). Notably, a greater 
increase in tumor latency was observed in the groups of mice pretreated with 3-
epiCA or MA compared to the UA-pretreated group (p<0.05; Mantel-Cox test).  
 
In summary, all of the triterpene compounds tested in this experiment significantly 
inhibited skin tumor promotion by TPA. UA along with OA, CA, 3-epiCA, MA, and 3-
epiMA effectively inhibited the formation of papillomas promoted by TPA. Notably, 3-
epiCA and MA exhibited the greatest inhibitory effect on papilloma multiplicity, 
incidence, and latency and these two compounds were significantly more effective at 
inhibiting skin tumor promotion when compared to the UA-pretreated group. As 
shown in Figure 3-1D, there were no significant differences in body weight between 
any of the triterpene-treated groups and the TPA-only treated group (p>0.05, Mann-





with the triterpenes indicating that the topical dosage of triterpenes used in this 



















Figure 3-1: Anti-tumor skin tumor promoting effects of UA and related 
triterpenes found in P. frutescens. 
Female ICR mice 7 weeks old (n=30/group) were initiated with 25 nmol DMBA. Two 
weeks after initiation with DMBA, mice were pretreated with either acetone vehicle 
(0.2 ml), UA (2 mol), OA (2 mol), CA (2 mol), 3-epiCA (2 mol), MA (2 mol) and 
3-epiMA (2 mol) 30 min prior to each 6.8 nmol TPA treatment. All treatments were 
given twice-weekly. The number and incidence of papillomas as well as average 
body weights were measured once weekly for 25 weeks. A. Effect of UA and related 
triterpenes found in P. frutescens on tumor multiplicity (i.e., Y-axis on the graph 
shows the average number of papillomas per mouse). B. Effect of UA and related 
triterpenes found in P. frutescens on tumor incidence. C. Effect of UA and related 
triterpenes found in P. frutescens on tumor latency. D. Average body weight (g) per 
mouse. No significant difference was observed in body weight between triterpenes-
untreated group and triterpenes-treated groups. **, p ≤ 0.05 when compared to TPA-
treated group; and #, p ≤ 0.05 when compared to UA+TPA-treated group. Mann-
Whitney U test was used for tumor multiplicity and body weight. For tumor incidence, 
Fisher‟s exact test was used. Statistical analysis of tumor latency (i.e., tumor free 








Table 3-1. Effect of UA and related triterpenes present in P. frutescens on 
tumor multiplicity and tumor incidence. 
 
**, p ≤ 0.05 when compared to TPA-treated group; and #, p ≤ 0.05 when compared to 
UA + TPA-treated group. Mann-Whitney U test and Fischer‟s exact test were used 




















3.2.2 Effect of UA and related triterpenes found in P. frutescens on TPA-
induced epidermal hyperproliferation.  
Since epidermal proliferation is important for skin tumor development during tumor 
promotion in the two-stage skin carcinogenesis model [13, 14], histologic analyses 
were conducted to determine the effects of UA and the other triterpenes on TPA-
induced epidermal hyperplasia (epidermal thickness) and LI. The short-term 
treatment protocol was used for these experiments. As shown in Figure 3-2A and 3-
2B, TPA treatment increased both epidermal thickness and LI 48 h after the last 
treatment when compared to vehicle (acetone)-treated group (p<0.05; Mann-Whitney 
U test). Pretreatment with all of the triterpenes reduced both epidermal thickness and 
LI compared to the TPA-only treated group (p<0.05, Mann-Whitney U test). However, 
3-epiCA, MA and 3-epiMA inhibited epidermal thickness to a greater extent than UA 
and CA, 3-epiCA, and MA reduced the LI to a greater extent than UA (p<0.05; Mann-
Whitney U test). Overall, these data indicate that all compounds examined in this 
experiment effectively inhibited TPA-induced epidermal hyperproliferation with 












Figure 3-2: Effects of UA and related triterpenes from P. frutescens on TPA-
induced epidermal hyperproliferation in female ICR mice.  
The dorsal skin of mice (7-9 weeks of age; n=4/group) was shaved and then two 
days later treated with either acetone vehicle (0.2 ml), UA (2 mol), OA (2 mol), CA 
(2 mol), 3-epiCA (2 mol), MA (2 mol) and 3-epiMA (2 mol) 30 min prior to 6.8 
nmol TPA.  All treatments were given twice-weekly for two weeks. Forty eight hours 
later the last TPA treatment, dorsal skin was fixed in 10 % formalin-buffered solution, 
embedded in parafin and sectioned (4 m) for BrdUrd-staining. A. Representative 
BrdU-stained skin sections (20X magnification). B. Quantitative analyses of the 
effect of UA and related triterpenes found in P. frutescens on TPA-induced epidermal 
thickness and labeling index (% of BrdU-positive cells). The graphs represent mean 
± standard error of the mean (SEM). *, p ≤ 0.05 when compared to acetone-treated 
group; **, p ≤ 0.05 when compared to TPA-treated group; and #, p ≤ 0.05 when 






3.2.3 Effect of triterpenes on skin inflammation induced by TPA.  
The ability of UA, OA, AA, CA, 3-epiCA, MA and 3-epiMA to inhibit TPA-induced skin 
inflammation was evaluated by first examining effects on the dermal infiltration of 
inflammatory cells (i.e., mast cells and CD3 positive T-lymphocytes). As shown in 
Figure 3-3A and 3-3B, all compounds significantly reduced the number of mast cells 
(toluidine blue O-stained cells) in the dermis in the range from 40-62% (p<0.05; 
Mann-Whitney U test) compared to the TPA only treated group. Again, 3-epiCA and 
MA were most effective at reducing the number of infiltrated mast cells and showed a 
significantly greater inhibitory effect compared to the UA-pretreated group (p<0.05, 
Mann-Whitney U test). Similar results were also observed for the number of 
infiltrated T-lymphocytes (CD3 positive cells) induced by TPA where all of the 
triterpenes significantly reduced their number compared to the TPA-only group 
(p<0.05, Mann-Whitney U test) (Figure 3-3B). Again, 3-epiCA and MA were the most 
effective compounds at inhibiting dermal T-cell infiltration induced by treatment with 
















Figure 3-3: Effects of UA and related triterpenes found in P. frutescens on skin 
inflammation induced by TPA. Groups of female ICR mice (7-9 weeks of age; n=4) 
were shaved on the dorsal skin and two days later were treated with acetone vehicle 
(0.2 ml), UA (2 mol), OA (2 mol), CA (2 mol), 3-epiCA (2 mol), MA (2 mol) and 
3-epiMA (2 mol) 30min before 6.8 nmol TPA treatment.  All treatments were given 
twice-weekly for two weeks. Dorsal skin was collected 48 hrs after the last TPA 
treatment, fixed in formalin, embedded in paraffin, and 4 m sections stained with 
toluidine blue O solution or CD3 antibody. A. Representative toluidine blue O stained 
skin sections. B. Quantitative evaluation of the effect of UA and other triterpenes 
found in P. frutescens on TPA-induced mast cells infiltration in the dermis. The 
graphs represent mean ± SEM. C. Representative histologic skin sections of CD3+ 
staining. D. Quantitative evaluation of the effect of UA and other triterpenes found in 
P. frutescens on TPA-induced T-lymphocyte infiltration in dermis. *, p ≤ 0.05 when 
compared to acetone-treated group; **, p ≤ 0.05 when compared to TPA-treated 
group; and #, p ≤ 0.05 when compared to UA+TPA-treated group.  Mann-Whitney U 






3.2.4 Effect of triterpenes on TPA-induced inflammatory gene expression.  
As shown in Figure 4, qRT-PCR analyses showed that UA and the other related 
triterpenes inhibited TPA-induced inflammatory gene expression in the epidermis. In 
this regard, mRNA levels of the following genes were evaluated: Cox-2, Il17a, Il22, 
Cxcl1, Cxcl2, and Vegfa. The increased expression of Cox-2 mRNA following TPA 
treatment was significantly reduced by pretreatment with UA, OA, CA, 3-epiCA and 
MA (p<0.05; Mann-Whitney U test) (Figure 3-4). MA pretreatment led to the greatest 
reduction in Cox-2 mRNA and this reduction was greater than that observed in the 
UA pretreated group (p<0.05; Mann-Whitney U test). Furthermore, the induction of 
Vegfa by TPA was lowered significantly by pretreatment with AA, CA, 3-epiCA, and 
MA (p<0.05; Mann-Whitney U test). mRNA levels of Il17a and Il22 was also 
evaluated in this experiment. TPA treatment significantly increased the expression of 
both Il17a and Il22 (p<0.05; Mann-Whitney U test) (Figure 3-4). Notably, the 
increased expression of Il17a was significantly reduced in the groups pretreated with 
AA, CA, 3-epiCA, and MA and a greater inhibitory effect was observed in the 3-
epiCA- and MA-pretreated groups (p<0.05; Mann-Whitney U test) compared to the 
UA treated group. In addition, OA, AA, CA, 3-epiCA, and MA significantly inhibited 
TPA-induced Il22 expression (p<0.05; Mann-Whitney U test) while UA and 3-epiMA 
did not show a statistically significant decrease in the expression of Il22 induced by 
TPA. Again, 3-epiCA and MA produced the greatest inhibition of Il22 expression. 
 
We also investigated the effects of the triterpenes on proinflammatory chemokines, 
Cxcl1 and Cxcl2. As shown in Figure 3-4, the expression Cxcl1 and Cxcl2 was 
significantly increased by TPA treatment (p<0.05; Mann-Whitney U test). 





all of the compounds significantly inhibited the expression of Cxcl2 by TPA (p<0.05; 
Mann-Whitney U test). Notably, 3-epiCA and MA, were most effective and produced 
greater inhibition than UA on Cxcl2 mRNA expression (p<0.05, Mann-Whitney U test).  
 
Collectively, these data demonstrate that UA and related triterpenes found in P. 
frutescens inhibited inflammatory gene expression in the epidermis although some of 
these genes were differentially affected by the individual triterpenes. Notably, when 
looking at all the genes examined, 3-epiCA and MA produced the most significant 














Figure 3-4: Effects of UA and a series of related triterpenes found in P. 
frutescens on TPA-induced inflammatory gene expression. Female ICR mice (7-
9 weeks of age; n=4/group) were shaved on the dorsal skin and the two days later 
pretreated with acetone vehicle (0.2 ml), UA (2 mol), OA (2 mol), CA (2 mol), 3-
epiCA (2 mol), MA (2 mol) and 3-epiMA (2 mol) before TPA treatment.  All 
treatments were given twice-weekly for two weeks. Mice were sacrificed 6 hrs after 
the last TPA treatment and epidermal RNA was isolated to be subjected to qRT-PCR 
analysis. mRNA levels of Cox-2, Il17a, Il22, Cxcl1, Cxcl2, and Vegfa were 
normalized to Gapdh. The graphs represent mean ± SEM. *, p ≤ 0.05 when 
compared to acetone-treated group; **, p ≤ 0.05 when compared to TPA-treated 
group; and #, p ≤ 0.05 when compared to UA+TPA-treated group. Mann-Whitney U 














3.2.5 Effect of triterepenes on epidermal signaling pathways induced by TPA  
The effects of topical pretreatment with UA OA, AA, CA, 3-epiCA, MA and 3-epiMA 
on multiple signaling pathways induced by TPA in the epidermis were examined (see 
Figure 3-5, panels A and B). As shown in Figure 3-5A and 3-5B, groups pretreated 
with UA, OA, AA, CA, or 3-epiMA showed a slight inhibition of phosphorylation of 
IGF-1RY1135/1136 (not statistically significant). However, a statistically significant 
inhibition was observed in the groups pretreated with 3-epiCA and MA. The inhibitory 
effect of 3-epiCA on activation of IGF-1RY1135/1136 by TPA treatment was also 
significantly greater when compared to the UA-pretreated group (p<0.05; Mann-
Whitney U test). On the other hand, none of the triterpene compounds showed 
inhibition of TPA-induced p-EGFRY1086 levels. Evaluation of the effect of the 
triterpenes on p-SrcY416 levels was also examined. Significant inhibition of the 
phosphorylation of p-SrcY416 was observed in groups pretreated with CA, 3-epiCA, 
MA and 3-epiMA (p<0.05; Mann-Whitney U test). Again, similar to the result of IGF-
1R signaling, 3-epiCA was more effective at reducing p-SrcY416 levels than UA 
following treatment with TPA (p<0.05; Mann-Whitney U test). 
 
The inhibitory effect of the triterpenes was also examined on STAT3 phosphorylation 
(both the Y705 and the S727 sites) induced by TPA (Figure 3-5A and 3-5B). As 
shown in the figure, CA, 3-epiCA, MA and 3-epiMA significantly decreased the 
phosphorylation of STAT3 at S727 (p<0.05; Mann-Whitney U test) while rest of the 
compounds tested did not show a statistically significant reduction in p-STAT3S727 
level when compared to the TPA-only treated group. Notably, 3-epiCA, MA, and 3-
epiMA showed the greatest inhibitory effect (p<0.05; Mann-Whitney U test). In 





(p<0.05; Mann-Whitney U test) while the other compounds did not significantly alter 
STAT3 phosphorylation at this site. A downstream target of STAT3, Twist1, was also 
examined. Pretreatment with CA, 3-epiCA, MA, and 3-epiMA reduced the level of 
Twist1 induced by TPA (p<0.05; Mann-Whitney U test).  
 
Additional analyses were performed to examine the effect of the triterpenes on other 
signaling pathways such as Cox-2, JNK1/2, c-Jun, Pdcd4 and p27. As shown in 
Figure 3-5A and 5B, the level of Cox-2 protein was significantly reduced by all of the 
compounds except AA and the reduction by 3-epiCA and MA was greater than that 
observed in the UA-pretreated group (p<0.05; Mann-Whitney U test). In addition, all 
triterpenes excluding OA significantly reduced the phosphorylation of JNK1/2T183/Y185 
that was stimulated by TPA treatment (p<0.05; Mann-Whitney U test) and AA, CA, 3-
epiCA, MA and 3-epiMA had a significant inhibitory effect on TPA-induced c-Jun 
phosphorylation at S73. Notably, a greater reduction in p-c-JunS73 was observed in 
the groups pretreated with CA, 3-epiCA, and 3-epiMA (p<0.05; Mann-Whitney U test) 
compared with the UA-pretreated group. The effect of the pentacyclic triterpenes on 
tumor suppressor proteins, Pdcd4 and p27, was investigated. The decreased level of 
Pdcd4 after TPA treatment was partially reversed by CA, 3-epiCA, MA and 3-epiMA 
(p<0.05; Mann-Whitney U test) whereas none of compounds had significant effects 
on p27 levels following treatment with TPA.  
 
Several studies including those from our group have reported AMPK activators (e.g. 
Metformin, AICAR, compound C) inhibit skin cancer in vitro and in vivo [11, 105, 199], 
therefore the effect of the triterpenes on AMPK signaling following TPA treatment 





modest activation of AMPK (assessed by phosphorylation at T172). Pretreatment 
with UA did not significantly increase AMPKactivation while pretreatment with the 
other compounds tested significantly increased the phosphorylation of AMPK-T172 
above that observed following TPA treatment (p<0.05; Mann-Whitney U test). The 
status of SirT1 and LKB1 was also evaluated. As shown in Figure 3-5A and 3-5B, 
activation of LKB1 (phosphorylation at S428) was enhanced by pretreatment with CA, 
3-epiCA, MA and 3-epiMA (p<0.05; Mann-Whitney U test) while all triterpene 
compounds except UA significantly increased the level of SirT1 (p<0.05, Mann-
Whitney U test). As expected, phosphorylation of the downstream target of AMPK, 
Ulk1 at S555 was also elevated by pretreatment with AA, CA, 3-epiCA, MA and 3-
epiMA. Notably, the dramatic upregulation as seen in AMPK signaling after 3-epiMA 
pretreatment was also observed in the phosphorylation of Ulk1 at S555 after 
pretreatment with this compound.  
 
In summary, the data in Figure 3-5 demonstrate that pretreatment with the various 
triterpenes that were evaluated caused alterations in a number of signaling pathways 
important for skin tumor promotion by TPA. Several of the compounds, including 3-
epiCA and MA showed greater effects on a broad range of signaling pathways that 









Figure 3-5: Effects of UA and related triterpenes from P. frutescens on TPA-
induced epidermal signaling pathways in female ICR female. Groups of mice 
(n=4/group) were shaved on the dorsal skin and the two days later treated with 
acetone vehicle, UA (2 mol), OA (2 mol), CA (2 mol), 3-epiCA (ECA, 2 mol), MA 
(2 mol) and 3-epiMA (EMA, 2 mol) 30 min prior to 6.8 nmol TPA treatment.  All 
treatments were given twice-weekly for two weeks. Six hrs after the last TPA 
treatment, epidermal lysates were prepared for Western blot analysis. A. 
Representative Western blots for the effect UA and related triterpenes on TPA-
induced signaling pathways. B. Quantitative evaluation of the Western blot analysis. 
Phosho-proteins are normalized to both total protein and actin. The levels of twist1, 
Cox-2, Pdcd4, p27 and SirT1 were normalized to actin. The graphs represent mean 
± SEM of three independent experiments. *, p ≤ 0.05 when compared to acetone-
treated group; **, p ≤ 0.05 when compared to TPA-treated group; and #, p ≤ 0.05 
when compared to UA+TPA-treated group.  Mann-Whitney U test was used for 









In current study, all of the triterpenes tested significantly inhibited skin tumor 
promotion by TPA. 3-EpiCA and MA were the most effective compounds at inhibiting 
the development of papillomas and were more effective than the prototype and more 
widely studied UA. Mechanistic studies revealed that all of the tripterpenes tested 
had the ability to inhibit TPA-induced epidermal hyperproliferation and skin 
inflammation. Again, the overall inhibitory effects on epidermal proliferation and skin 
inflammation were the greatest in the groups pretreated with 3-epiCA or MA and 
significantly greater than seen in the UA +TPA group. Analysis of epidermal signaling 
pathways induced by TPA revealed that there were variable effects of the different 
compounds on individual signaling pathways. However, the greater ability of 3-epiCA 
and MA to inhibit skin tumor promotion was associated with greater reduction of Cox-
2 and Twist1 proteins and inhibition of activation (i.e., phosphorylation) of IGF-1R, 
Stat3 and Src. Collectively, the current data demonstrate that triterpenes from P. 
frutescens inhibit skin tumor promotion by inhibiting signaling pathways associated 
with epidermal proliferation and inflammation.  
 
Several of the pentacyclic triterpenes found in P. frutescens have been widely 
studied. In this regard, UA has been shown to have apoptotic, anti-inflammatory, and 
anti-tumorigenic effects [130, 135-137]. UA and OA are often found together in plants, 
including P. frutescens and possess similar pharmacological properties [129, 135-
137]. OA, like UA, also exhibits anti-inflammatory, gastro-protective, wound-healing, 
and anti-microbial propoerties [138, 139]. In addition, several studies have shown its 
anti-cancer effects in both in vitro and in vivo studies [127, 140]. OA inhibits 





and skin [141-144]. CA also exists in abundance in the plant kingdom, including 
bananas and loquat as well as P. frutescens [126, 200]. A number of studies have 
shown that CA has anti-diabetic, anti-oxidant, anti-inflammatory, apoptotic, and anti-
cancer activities. Its anti-cancer effects have not been as extensively studied in vivo 
although several in vitro studies have demonstrated growth inhibitory effects in 
cancer cell lines including gastric, colon, cervix, leukemia and lung [157-163]. MA, 
also known as crategolic acid, has been isolated from P. frutescens as well as other 
edible plants such as olive fruit, spinach, eggplant, mustard, basil and legumes [148]. 
Recently, the anti-proliferative or apoptotic properties of MA have been demonstrated 
in various cancer cell lines such as colon, liver, bladder, uterus and breast [149-154]. 
 
As noted in the Introduction, of the compounds evaluated in the current study, only 
UA and OA have previously been shown to inhibit skin tumor promotion by TPA [107, 
108, 127, 128]. In a recent study by our group, topical pretreatment with 2 mol of 
UA reduced the number of TPA promoted skin papillomas by 39% [108]. In the 
current study, the same dose of UA given before TPA reduced papilloma formation 
by 42 %. Thus, these two independent studies show that UA when given topically to 
the same mice (female ICR) and under similar experimental conditions produced 
essentially the same level of inhibition of tumor promotion. Tokuda et al. reported that 
topical application of OA inhibited skin tumor promotion by TPA in female ICR mice 
using considerably lower doses [127]. In this study, they also compared the anti-
tumor promoting effect of OA with UA using two different treatment protocols. Both 
OA and UA inhibited skin tumor promotion by TPA to a similar extent when the 
compounds were given prior to each TPA application over a 20 week period. 





when given only once prior to the first TPA application. The mechanisms for the 
observed inhibition of skin tumor promotion by both OA and UA in either protocol 
were not reported in this earlier study. In the current study, UA and OA given at the 
same topical dose produced a very similar inhibition of skin tumor promotion (42% vs 
35%, respectively; Table 3-1). The potential anti-cancer effects of CA and MA have 
been reported in a number of in vitro studies, however, only a few studies have 
evaluated their inhibitory effects in cancer models. Li et al. reported that 
subcutaneous administration of MA (10 and 50 mg/kg) inhibited growth of pancreatic 
cancer cells in a xenograft mouse model [155]. In another study, MA was given in the 
diet (100 mg/kg) to APC Min/+ mice and was shown to reduce colon carcinogenesis 
by 45 % [156]. In addition, MA inhibited both the size and weight of bladder tumors in 
a xenograft mouse model [152]. Recently, Yoo et al. have reported that CA possess 
suppressive effects on angiogenesis and lymphangiogenesis in vivo using a CT-26 
colon carcinoma animal model [164].  
 
In contrast to UA and OA, no studies to date have reported on the anti- skin tumor 
promoting effects of CA, 3-epiCA, MA and 3-epiMA. Therefore, our results report for 
the first time the ability of these triterpenoids that are found together in P. frutescens 
to inhibit skin tumor promotion by TPA in the two-stage skin carcinogenesis model. 
As shown in Figure 3-1 and Table 3-1, all 4 of these compounds had the ability to 
inhibit skin tumor promotion by TPA when given topically 30 min prior to each TPA 
application. This was seen primarily in the ability to inhibit the formation of 
papillomas that were promoted by TPA. Significant effects were also observed on 
tumor latency. When compared to the activity of UA for inhibition of skin tumor 





skin tumor promotion as assessed by effects on tumor multiplicity, tumor incidence, 
and tumor free survival (i.e., latency) (see again Figure 3-1 and Table 3-1).  
 
In our previous study, topical application of 2 mol UA prior to TPA application was 
shown to significantly inhibit Cox-2, NF-B p65S536 and AktT308 signaling as well as 
reductions in activation of SrcY416, STAT3Y705, and JNK1/2T183/Y185 [108]. In the current 
study, the effect of 2 mol of UA, OA, AA, CA, 3-epiCA, MA and 3-epiMA were 
compared for their effects on some of these same pathways as well as others 
(Figure 3-5). All compounds reduced Cox-2 expression and the levels of p-JNK1/2 
although the reduction in Cox-2 level with AA pretreatment was not statistically 
significant. In addition, all of the compounds reduced the levels of p-c-SrcY416 
although the values with UA, OA and AA were not statistically significant. Some of 
the triterpenes, notably, 3-epiCA and MA produced a greater degree and a broader 
range of inhibition of signaling pathways. Further analyses revealed that these two 
compounds, in addition to inhibiting Cox-2, p-JNK1/2T183/Y185 and p-SrcY416, 
significantly reduced p-IGF-1RY1135/1136, p-Stat3S727, Twist1, p-c-JunS73 and increased 
Pdcd4, p-AMPK-172, Sirt1, p-LKB1S428 and p-ULK1S555.  Thus, the greater 
inhibitory activity of these two compounds was associated with a greater ability to 
modulate multiple growth factor and inflammatory signaling pathways in the 
epidermis.   
 
During tumor promotion stage, repeated topical treatments of TPA produce and 
maintain chronic epidermal cell proliferation [13]. Initiated cells have a selective 





undergo clonal expansion to form pre-malignant papillomas [13, 14, 21]. Therefore, 
we examined the anti-proliferative effect of the triterpenes on TPA-induced epidermal 
hyperproliferation. Our previous data indicated that topical treatment of UA inhibited 
both epidermal thickness and LI induced by TPA [108]. In the current study, UA and 
the other related triterpenes significantly inhibited TPA-induced epidermal thickness 
and LI. However, 3-epiCA and MA, again showed the greatest effect on epidermal 
hyperproliferation and these two compounds were more effective than the group 
pretreated with UA.  
 
Another important aspect of tumor promotion is chronic inflammation. Upregulation 
and secretion of pro-inflammatory molecules by TPA treatment recruits inflammatory 
cells such as mast cells, monocytes, leukocytes, T-and B-lymphocytes,, and 
macrophages into the dermis [22, 23]. The number of these cells is increased in the 
dermis adjacent to the epidermis and they promote tumor growth by producing 
growth factors, cytokines, and chemokines [22, 23]. Data previously published from 
our group suggested that multiple applications of TPA increased the number of 
dermal infiltrated inflammatory cells such as mast cells, T-lymphocytes, and 
macrophages in mouse skin [10, 108]. Topical treatment with UA and other 
chemopreventive agents such as rapamycin and resveratrol, have been shown to 
decrease the number of these cells in the dermis following TPA treatment [10, 108]. 
In addition, Banno et al. demonstrated the anti-inflammatory effect of UA and some 
other triterpenes including OA, AA, CA, 3-epiCA, CA, MA and 3-epiMA on TPA-
induced ear edema [126, 201]. In this study, they determined ID50 values of 
triterpenoids and the range of ID50 on TPA-induced inflammation in mouse ear was 





among the groups pretreated with UA, AA, CA, 3-epiCA, MA or 3-epiMA dissolved in 
MeOH-CHCl3-H2O vehicle. However, given the higher ID50 value (0.3 mg/ear) of OA, 
OA was less effective than the others. As shown in Figure 3-3, UA and related 
triterpenes significantly decreased the number of dermal mast cells and T-
lymphocytes induced by TPA. Again, the most effective compounds were 3-epiCA 
and MA. In addition, these two compounds were the most effective overall at 
inhibiting TPA-induced inflammatory gene expression (Figure 3-4)  
 
In conclusion, evaluation of a series of pentacyclic triterpenes found in P. frutescens 
showed that all of these compounds inhibited skin tumor promotion by TPA and that 
3-epiCA and MA were more effective than UA. The inhibitory effects of all 
compounds and the greater effect of several compounds such as 3-epiCA and MA 
on skin tumor promotion were due to the reduction of epidermal hyperproliferation, 
skin inflammation, and alterations in a number of epidermal signaling pathways 
critical for tumor promotion. Although some of these compounds were previously 
shown to have anti skin tumor promoting activity (UA and OA), this is the first 
comprehensive comparison of a series of pentacyclic triterpenes found in P. 
frutescens for their effects on skin tumor promotion in vivo and included new 
compounds not previously evaluated (i.e., CA, 3-epiCA MA and 3-epiMA) . 
Furthermore, we found that two of these compounds were more active than UA and 
have provided a potential mechanistic basis for this increased activity. Overall, these 
compounds and especially 3-epiCA and MA, deserve further evaluation for their 







Chapter 4. Effect of the combination of UA and Res on skin tumor promotion 
by TPA1 
4.1 Introduction 
UA is a natural pentacyclic triterpenoid carboxylic acid found in many plants including 
P. fructescen (Japanese basil), rosemary, apples, elder flowers and many others. UA 
has been shown to have apoptotic, anti-inflammatory and anti-tumorigenic effects in 
various cancer models including prostate, ovary, stomach, intestine, and skin [126, 
127, 129]. Further studies have revealed that UA has broad-spectrum anti-
carcinogenic effects including prevention of DNA damage, inhibition of EGFR/MAPK 
signaling, inhibition of angiogenesis, activation of apoptotic pathways, and inhibition 
of Akt/mTOR, NF-B, Cox-2, and STAT3 signaling pathways [129, 130]. Although 
several studies have reported that UA inhibited carcinogen and 12-O-
tetracanoylphorbol-13-acetate (TPA)-induced inflammation, hyperplasia and tumor 
promotion in mouse skin [107, 126, 127], its inhibitory mechanism on skin tumor 
promotion is not fully understood. Recently, several studies reported that UA has an 
anti-obesity effect and mimics some of the effects of calorie restriction (CR) by 
modulating Akt/mTOR signaling pathways [131-133]. UA has also been shown to 
activate the LKB1/AMPK pathway for inhibition of adipogenesis [134].  
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Res is a phytoalexin and is present in grapes, berries, peanuts and red wine. Res 
has been shown to have cardiovascular benefit and anti-diabetic effects in both mice 
and humans. In addition, Res was shown to inhibit skin tumor promotion and also 
inhibit the growth of many cancer cell lines, including breast, prostate, colon and liver 
[107, 167, 169, 172, 179]. Mechanisms associated with the anti-tumor promoting 
effects of Res include inhibition NF-B, AP-1, and Cox-2 [167-169]. Several reports 
have suggested that Res also mimics some of the effects of CR on life span in 
worms and other model organisms, especially by inhibiting inflammation and mTOR 
signaling [170, 173]. Res also mimics effects of CR by increasing SirT1 and AMPK 
activation [171]. Boily et al. have suggested that the anti-promoting effect of Res on 
mouse skin is at least partially mediated by SirT1 [106]. 
 
Emerging evidence suggests that combinations of phytochemicals may be an 
effective strategy to achieve a greater chemopreventive effect than with single 
agents [174, 180, 181]. Several studies have shown that combinations of natural 
compounds can produce potential synergistic inhibitory effects in various cancers 
(e.g., Res + grape seed extract and ellagic acid + grape seed extract) [176-181]. 
Recently, Junco et al. reported that Res potentiates the growth inhibitory effect of UA 
in mouse skin papilloma and carcinoma cell lines [202]. Thus, combining agents may 
provide the most rational and effective approach to cancer chemoprevention. In 
addition, using combinations of phytochemicals may produce overall effects that 
more similarly mimic CR.  
 
In the present study, topical treatment with a combination of UA + Res produced a 





Further mechanistic studies revealed that this combination produced a greater 
inhibition of multiple growth factor and inflammation signaling pathways as well as 
greater upregulation of tumor suppressor genes such as p21 and PDCD4. 
Interestingly, the combination of UA + Res induced a dramatic increase of p-AMPK-

Thr172 and its downstream target p-Ulk1Ser555. Collectively, the current data suggest 
that combined treatment of UA + Res is a more effective inhibitor of skin tumor 
promotion than either UA or Res given alone. The mechanism for this greater 










4.2.1 Effect of UA + Res on skin tumor promotion by TPA. 
The ability of a combination of UA + Res to inhibit skin tumor promotion by TPA was 
evaluated in ICR mice maintained on either an overweight control diet or a diet-
induced obesity diet (DIO diet). After completion of the tumor experiment, the tumor 
responses in both diet groups were similar for all groups (see Figs. 4-1A and 1B). 
Therefore, the data for the corresponding treatment groups on each diet were 
combined as presented in Fig. 4-2. As shown in Fig. 4-2B, pretreatment with UA or 
Res alone inhibited tumor multiplicity by 38.6% and 20.8%, respectively. The 
reduction in tumor multiplicity with UA was statistically significant (p<0.05; Mann-
Whitney U test) compared to the group treated with TPA alone. Pretreatment with the 
combination of UA + Res resulted in 56% reduction in tumor multiplicity that was 
significantly lower when compared to both the Res + TPA and UA + TPA groups 
(p<0.05; Mann-Whitney U test). Furthermore, the incidence of papillomas in the mice 
treated with UA + Res was significantly lower than that observed in the TPA and Res 
+ TPA treated groups (Fig. 4-2A) (p<0.05; Fisher‟s exact test) but not the UA + TPA 
group. An effect on tumor latency was also observed as shown in Fig. 4-2C. In this 
regard, the percent of tumor-free mice treated with the combination of UA + Res was 
significantly higher than that of the TPA only and Res + TPA groups over the 23 week 
observation period (p<0.05; Mantel-Cox test) but not the UA + TPA treated group.  
 
As shown in Fig. 4-2D, the combination of UA + Res significantly reduced the size of 
papillomas compared to the TPA only group as well as both the UA + TPA and Res + 
TPA groups (p<0.05; Mann-Whitney U test). Thus, the combination was more 





either agent given alone.  
 
Body weight gain for the 23 week experiment for each group is shown in Fig. 4-1C 
and 1D. As expected, there were significant differences in body weight between 
untreated mice on the overweight control and DIO diets (41.57 g ± 2.49 and 56.57 g 
± 2.39, respectively; p< 0.05; Mann-Whitney U test). No significant differences were 
observed in body weight between the treated groups in mice on either the control 
diet or DIO diet. Overall, these data suggest that the combined treatment of UA + 
Res, at the doses used, had a greater inhibitory effect on skin tumor promotion 
compared to the groups pretreated with either of the compounds alone and with no 









Figure 4-1. Effect of UA + Res on skin tumor promotion in female ICR mice on 
the overweight control and DIO diet (Panels A and B, respectively) and on 
weight gain (Panels C and D, respectively). Panel A, tumor multiplicity in mice 
maintained on the overweight control diet. Panel B, tumor multiplicity in mice on the 
DIO diet. Panel C, average body weight of groups of mice on the control diet. Panel 
D, average body weight of groups of mice on the DIO diet. All groups on the DIO diet 
had body weights significantly greater than those on the control diet (*, p<0.05; 
Mann-Whitney U test). No differences in body weight were observed between 







Figure 4-2. Effect of UA + Res on skin tumor promotion in ICR mice. Panel A, 
Incidence of tumors (percentage of mice with papillomas). The percentage of mice 
with papillomas in the group treated with UA + Res +TPA was significantly lower than 
TPA (**) or Res + TPA (ǂ) treated groups (p<0.05; Fisher‟s exact test). Panel B, 
tumor multiplicity (average number of papillomas per mouse). Both the UA and the 
UA + Res pretreated groups had significantly reduced tumor multiplicity compared to 
the TPA-treated group (**, p< 0.05). The tumor multiplicity in the UA + Res + TPA-
treated (#, p<0.05; Mann-Whitney U test) was also significantly lower than both UA + 
TPA and Res + TPA-treated group. Panel C. tumor latency (tumor free survival). 
Significant differences were observed between the UA + TPA and UA + Res + TPA 
compared to the TPA only group (**, p<0.05; Mantel-Cox test). Percent of tumor free 
mice in the combination group (ǂ, p<0.05; Mantel-Cox test) was greater than the Res 
+ TPA group. Panel D, tumor size. The surface area of papillomas was measured at 
the 23rd week. **, p<0.05 when compared to TPA group; †, p<0.05 when compared 
to UA + TPA group; and #, p<0.05 when compared to both the Res + TPA and UA + 







4.2.2 Effect of UA + Res Treatment on TPA-induced epidermal 
hyperproliferation 
As shown in Figs. 4-3A and 4-3B, UA or Res alone significantly reduced BrdU 
incorporation and epidermal thickness following TPA treatment (p<0.05; Mann-
Whitney U test). However, treatment with the combination of UA + Res produced a 
greater inhibition of BrdU incorporation and epidermal thickness induced by TPA 
compared to that observed with either of the compounds given alone with TPA 
(p<0.05; Mann-Whitney U test).  
 
As shown in Fig. 4-4, LRCs in acetone-treated mice were confined to the hair follicle 
bulge-region as expected based on previous studies [182, 185]. However, after a 
two-week treatment regimen with TPA, the LRCs can be seen moving up and out of 
the hair follicle into the interfollicular epidermis (Fig. 4-4A). Pretreatment with UA or 
Res partially inhibited the effect of TPA on proliferation and migration of LRCs. 
However, treatment with the combination of UA + Res prior to application of TPA 
produced a greater inhibitory effect on the proliferation and migration of these cells 








Figure 4-3. Effect of UA + Res on TPA-induced epidermal hyperproliferation in 
ICR mice. Female ICR mice at 7-8 weeks of age maintained on standard chow diet 
were treated topically with the short-term protocol. Dorsal skin was collected at 48 
hrs after the last treatment for histological evaluation. Sections were stained with 
H&E and for BrdU incorporation. Panel A, representative sections of BrdU stained 
skin. Arrows indicate BrdU-positive cells. Magnification, X 20 Panel B, quantitative 
analysis of the effects of UA, Res or UA + Res on TPA-induced epidermal thickness 
and labeling index (% BrdU positive cells). The values in panel B represent the 
means ± SEM. *, p<0.05 when compared to the acetone treated group; **, p<0.05 
when compared to the TPA treated group; †, p<0.05 when compared to the UA + 
TPA group; #, p<0.05 when compared to UA + TPA and Res + TPA group. All 














Figure 4-4. Impact of UA + Res on the proliferation/migration of hair follicle 
stem/progenitor cells after TPA treatment in female FVB mice. Mice at 10-days 
of age were injected with BrdU (50 µg/g B.W) every 12 hrs over two days and then 
70 days later mice were treated topically using the multiple treatment protocol with 
acetone vehicle, TPA (6.8 nmol), UA (2 µmol) + TPA, Res (2 µmol) + TPA or UA (2 
µmol) + Res (2 µmol) + TPA. Dorsal skin sections were collected and subjected to 
BrdU staining for the presence of labeling-retaining cells (LRCs) as described in 
Materials and Methods. Panel A, representative sections of BrdU-stained skin. 
Arrows indicate the positions of BrdU-labeled cells in the various skin sections. 
Magnification, X 20 Panel B, quantitative evaluation of the effect of UA, Res, or UA + 
Res on TPA-induced proliferation/migration of hair follicle stem/progenitor cells. 
LRCs in the hair follicle and epidermis were counted and quantitated as previously 
described [182]. *, p<0.05 when compared to acetone group; **, p<0.05 when 
compared to TPA group; and #, p<0.05 when compared to UA + TPA and Res + TPA 






4.2.3 Effect of UA + Res on TPA-induced epidermal signaling pathways. 
As shown in the Fig. 4-5A and 5B, UA + Res significantly inhibited TPA-activated p-
STAT3Tyr705, p-AktThr308, p-NF-B p65Ser536, p-JNK1/2Thr183/Tyr185, p-c-JunSer73, and p-
p38 MAPKThr180/Tyr182, whereas UA or Res alone either produced no significant effects 
or a moderate inhibition of phosphorylation of these proteins relative to the 
combination. Cox-2 induction by TPA was not significantly decreased by 
pretreatment with either UA or Res alone, however, the combination of UA + Res 
produced a statistically significant inhibition of Cox-2 induction by TPA. The levels of 
several tumor suppressors were also evaluated (see again Fig. 4-5A and 5B). The 
combination of UA + Res significantly reversed the effect of TPA on PDCD4 and p21 
levels while pretreatment with either compound alone had no effect. In contrast, 
none of the treatments reversed the effects of TPA treatment on p27 levels.  
The phosphorylation of both EGFRTyr1086 and SrcTyr416 was also significantly inhibited 
by the combination of UA + Res at the doses and time points examined whereas 
neither UA nor Res alone significantly inhibited phosphorylation of these proteins. On 
the other hand, the increased level of Fas induced by TPA was decreased by 
treatment with Res alone and the combination of UA + Res but not with UA. Again, 
the combination was the most effective at inhibiting the increase in Fas seen 
following treatment with TPA.  
 
As shown in Fig. 4-6A and 6B, treatment with TPA alone produced a ~2.5-fold 
increase in p-AMPK-Thr172 compared to the acetone treated control group. Both UA 
and Res when given with TPA further increased p-AMPK-Thr172, while the 
combination of UA + Res together with TPA produced an even greater activation of 





(p<0.05). The level of SirT1 was not changed by treatment with TPA or pretreatment 
with any of the compounds given together with TPA, including the combination of UA 
+ Res (again see Fig. 4-6A and 6B). TPA treatment reduced the level of p-LKB1Ser428 
compared to the acetone group, however, neither UA nor Res had any further effect. 
In contrast, the level of p-LKB1Ser428 was further decreased when the combination of 
UA + Res was given before TPA treatment. TPA treatment led to activation of 
mTORC1 signaling as previously reported [10, 182, 203], however, the levels of p-
mTORC1Ser2448 and its downstream target, p-S6-ribosomal proteinSer240/244, were not 
affected by treatment with UA, Res or the combination of UA + Res. Notably, the 
level of p-Ulk1Ser555 was significantly increased when the combination of UA + Res 
was given together with TPA. The combination of UA + Res when given together with 
TPA significantly increased the level of LC3IIB compared to the acetone, TPA and UA 
+ TPA groups while the levels of ATG5 and Beclin1 that were reduced by TPA 



















Figure 4-5. Effect of UA + Res on TPA-induced signaling pathways in epidermis 
of female ICR mice. Western blot analyses were performed using pooled epidermal 
protein lysates from mice (n=4-5/group) receiving treatment with the short-term 
protocol. Panel A, representative Western blot analyses of multiple signaling 
pathways. Panel B, quantitative evaluation of Western blot data. Values represent 
means ± SEM from at least 3 independent experiments. *, p<0.05 when compared to 
the acetone treated group; **, p<0.05 when compared to the TPA treated group; †, 
p<0.05 when compared to the UA + TPA treated group; ǂ, p<0.05 when compared to 
the Res + TPA treated group; and #, p<0.05 when compared to the UA + TPA and 













Figure 4-6. Effect of UA + Res on TPA-induced AMPK and mTORC1 signaling 
pathways in epidermis of female ICR mice. Western blot analyses were performed 
using pooled epidermal protein lysates from mice (n=4-5/group) that received 
multiple treatments with short-term protocol. Panel A, representative Western blot 
analyses. Panel B, quantitative evaluation of the effect of UA, Res or UA + Res on 
TPA-induced AMPK- signaling pathway. Values represent means ± SEM from at 
least 3 independent experiments. *, p<0.05 when compared to acetone group; **, 
p<0.05 when compared to TPA group; †, p<0.05 when compared to UA + TPA group; 
ǂ, p<0.05 when compared to the Res + TPA treated group; and #, p<0.05 when 
compared to UA + TPA and Res + TPA group. The Mann-Whitney U test was used 












4.2.4 Effect of UA + Res on TPA-induced inflammation and inflammatory gene 
expression.  
As shown in Fig. 4-7A, the levels of IL-1, IL-1 IL-22 and Cox-2 mRNA were 
increased following treatment with TPA (given twice weekly for two weeks) and 
significantly decreased in the UA + Res pretreated group (p<0.05; Mann-Whitney U 
test). With the exception of UA pretreatment on Cox-2 mRNA, neither UA nor Res 
pretreatment significantly reduced the mRNA levels of these inflammatory genes. As 
shown in Figs. 4-7B pretreatment with UA and Res decreased the number of mast 
cells in the dermis seen following TPA treatment, however, an additional decrease in 
the number of dermal mast cells was observed after treatment with UA + Res + TPA 
(p<0.05; Mann-Whitney U test). UA alone and UA + Res also produced a significant 
decrease in the number of CD45+ cells in dermis (p<0.05) (Fig. 4-7C). Again, the 
combination of UA + Res produced the greatest reduction in the numbers of both 
mast cells and CD45+ cells.  Representative stained sections for mast cells and 







Figure 4-7. Effect of UA + Res on TPA-induced inflammatory gene expression 
and inflammatory cell infiltration. Epidermal RNA samples were prepared from 
groups of female ICR mice (n=4-5/group) treated using the short-term protocol. RNA 
samples were then subjected to qRT-PCR analysis as described in Materials and 
Methods. Panel A, qPCR analysis of IL-1, IL-1, IL-22, and Cox-2. mRNA levels of 
IL-1, IL-1, and IL-22 were normalized to 18S and the mRNA level of Cox-2 was 
normalized to GAPDH. Panel B, quantitative evaluation of the effect of UA, Res and 
UA + Res on the number of mast cells in the dermis 48 hrs after the last TPA 
treatment. Positive cells were counted per 200 mm2. Panel C, quantitative analysis 
of the effect of UA, Res and UA + Res on the number of CD45 positive cells in the 
dermis 48 hrs after the last TPA treat. Positive cells were counted per 200 mm2. The 
graphs in all cases represent means ± SEM of at least 3 independent experiments. *, 
p<0.05 when compared to acetone group; **, p<0.05 when compared to TPA group; 
†, p<0.05 when compared to UA + TPA group; ǂ, p<0.05 when compared to Res + 
TPA group; and #, p<0.05 when compared to UA + TPA and Res + TPA group. The 











Figure 4-8. Effect of UA + Res on TPA-induced dermal infiltration of 
inflammatory cells. Panel A, representative sections of toluidine blue O stained skin. 
Panel B, representative sections of CD45+ stained skin. Arrows in each panel 









4.2.5 Effect of UA + Res on NF-B, Egr-1, and AP-1 DNA binding activities 
induced by TPA. 
Treatment with TPA significantly increased the amount of NF-B, Egr-1 and AP-1 
bound to their consensus DNA binding oligos (Figs. 4-9A-C and Figs 4-10A-C). The 
TPA-induced increase in DNA binding activity of all three transcription factors was 
significantly reduced by pretreatment with the combination of UA + Res. 
Pretreatment with UA or Res alone significantly reduced binding of NF-B and UA 
pretreatment significantly reduced binding of AP-1. Thus, the combination of UA + 
Res was highly effective at inhibiting the activation of all three of these transcription 
factors by TPA. Additionally, the nuclear translocation of NF-B, Egr-1 and AP-1 
induced by TPA was also significantly inhibited by UA + Res to a greater extent than 













Figure 4-9. Effect of UA + Res on DNA binding activity and nuclear 
translocation of NF-B, Egr-1, and AP-1 induced by TPA. Groups of female ICR 
mice (4-5 mice per group) on the control diet were treated with the short-term 
protocol. Pooled epidermal nuclear and cytosolic fractions were obtained. The 
nuclear fractions were then subjected to EMSA and Western blot analyses. Western 
blot analyses were also performed with the epidermal cytosolic fractions. Panels A-C, 
quantitative analysis of EMSA for NF-B, Egr-1 and AP-1, respectively. Panels D-F, 
quantitative evaluation of Western blot data for cytosolic levels of NF-B, Egr-1, and 
AP-1, respectively. Panels G,-I, quantitative analysis of Western blot data for nuclear 
translocation of transcription factors NF-B p65, Egr-1, and AP-1, respectively. The 
graphs represent mean values ± SEM of at least 3 independent experiments. *, 
p<0.05 when compared to acetone group; **, p<0.05 when compared to TPA group; 
ǂ, p<0.05 when compared to Res + TPA group; and #, p<0.05 when compared to UA 









Figure 4-10. Representative blots showing the effect of UA + Res on DNA 
binding activity and nuclear translocation of NF-B, Egr-1, and AP-1 induced 
by TPA. Panels A-C, representative EMSA blots for NF-B, Egr-1, and AP-1, 
respectively. Panels D-F, representative Western blot analyses for cytosolic and 


















In the present study, topical application of UA + Res followed by TPA treatment 
inhibited skin tumor promotion to a greater extent when compared to the groups 
treated with either Res + TPA or UA + TPA alone. Further analyses revealed that the 
greater ability of the combination to inhibit skin tumor promotion correlated with a 
greater ability to inhibit epidermal proliferation induced by TPA. In addition, combined 
treatment with UA + Res produced greater inhibitory effects on TPA-induced 
epidermal signaling pathways including EGFR, STAT3, Fas, Src, Akt, Cox-2, NF-B, 
p38 MAPK, and JNK1/2. Notably, treatment with the combination also increased the 
levels of the tumor suppressor proteins p21 and PDCD4 compared to the groups 
treated with the individual compounds. Both UA and Res treatment followed by TPA 
increased AMPK-activation, however, the combination of UA + Res together with 
TPA produced an even greater activation of AMPK- Further studies revealed that 
the activation of NF-B, Egr-1, and AP-1 (DNA binding activity and nuclear 
translocation) were significantly inhibited by the combination of UA + Res compared 
to the groups treated with either UA or Res alone. The combination also produced 
greater effect on TPA-induced inflammation and inflammatory gene expression. 
Overall, the current data indicate that combined treatment with UA + Res led to a 
greater inhibitory effect on skin tumor promotion than either compound alone via 
effects on multiple events and pathways critical to the process of skin tumor 
promotion.  
 
As noted in the Introduction, UA was previously shown to have inhibitory effects on 





also shown to be as an effective inhibitor on skin tumor promotion [107, 167, 169, 
204] along with inhibitory effects on breast, colorectal, hepatic, pancreatic, and 
prostate cancers [172]. Recently, several studies have shown potential combinatorial 
chemopreventive effects with these agents in preclinical models of cancer. For 
example, melatonin was shown to potentiate the inhibitory effect of UA on 
proliferation and apoptosis in colon cancer cells by modulating multiple signaling 
pathways including caspases, PARP, NF-B and Cox-2 [205]. Kowalczyk et al. [107] 
tested a combination of 2% calcium D-glucarate (CG) given in the diet, with either 
2.5 μmol of Res or 1 μmol of UA applied topically in two-stage skin carcinogenesis 
model. In this study, UA applied alone and in combination with CG showed inhibitory 
effects on skin tumor incidence and multiplicity. 
 
Combinations of Res with other phytochemicals have been shown to have a greater 
inhibitory effect in several tumor models. For example, combined dietary 
administration of Res, quercetin and catechin (combinations at 0.5, 5 or 25 mg/kg) 
reduced primary tumor growth of breast cancer xenografts in a nude mouse model 
[206]. Res + black tea polyphenol inhibited mouse skin tumor growth by modulating 
MAPKs and p53 [204]. In other studies, Res + curcumin produced a better 
chemopreventive effect by maintaining adequate zinc and regulating p21 and Cox-2 
level during lung carcinogenesis [207]. Genistein + Res also reduced the most 
severe grade of prostate cancer in the SV-40 tag rat [177].  
 
As shown in the current study, the combination of UA + Res was a more effective 





dose used and this was true for both tumor multiplicity and tumor size (see again Fig. 
4-2). Although we did not design the current studies to analyze the development of 
squamous cell carcinomas (SCCs), papillomas are considered premalignant tumors 
and previous studies have shown that reductions in numbers of papillomas leads to 
reductions in SCCs [11, 14, 121]. As noted above, previous studies have shown that 
UA broadly inhibited a number of signaling pathways including EGFR, MAPK, 
Akt/mTOR, NF-B, Cox-2 and STAT3 in a variety of cell types, including mouse 
epidermis in vivo [129, 130]. Furthermore, mechanisms associated with the anti-
tumor promoting effects of Res include modulation of NF-B, Cox-2, mTORC1, and 
SirT1 [106, 167, 169, 171]. In our current study, we evaluated a number of 
oncogenic signaling molecules including EGFR, Src, STAT3, Fas, NF-B, Akt, p38, 
JNK1/2, c-Jun, and mTOR as well as the tumor suppressors p27, p21, PDCD4, and 
AMPK. As shown in Figs. 4-5 and 4-6 we found that the combination of UA + Res 
was more effective at altering these pathways during tumor promotion than either UA 
or Res given alone. In particular, the combination was significantly more effective at 
inhibiting TPA-induced activation (phosphorylation) of EGFR, Src and p38 MAPK 
and at altering the levels of Fas (decrease) and p-AMPK-Thr172and p21 (increase) 
compared to either UA or Res given alone. In addition, the combination of UA + Res 
produced the greatest inhibition of NF-B, Egr-1 and AP-1 DNA binding activities 
and nuclear translocation (Figs. 4-9 and 4-10). All three of these transcription factors 
are known to be upregulated during skin tumor promotion and skin carcinogenesis 
[21, 208]. Thus, the combination of UA + Res produced a more global and robust 






TPA-induced epidermal hyperproliferation is required for its tumor promoting activity 
[13, 14, 21]. Previous studies have shown that topical treatment of both 1 μmol of UA 
and 2 μmol of Res reduced TPA-induced BrdU incorporation in SENCAR mouse skin 
[107]. In the current study, we observed that the combination of UA + Res together 
with TPA at a dose of 2 μmol each inhibited epidermal hyperproliferation to a greater 
extent than with either compound alone at the same dose. The greater inhibition of 
TPA-induced epidermal hyperproliferation with the combination was likely due to the 
greater effects observed on the multiple signaling pathways noted above. Skin 
inflammation is also known to be an important component of the process of skin 
tumor promotion by TPA involving the production of pro-inflammatory cytokines and 
infiltration of inflammatory cells [21, 23, 209]. Again, as seen with the analyses of 
epidermal proliferation, the combination produced greater inhibition of inflammation. 
In this regard, the combination of UA + Res inhibited to a greater extent the 
increased expression of IL-1, IL-1, IL-22 and Cox-2 seen following treatment with 
TPA. In addition, as shown in Fig. 4-7B, the number of mast cells was decreased by 
either UA or Res treatment followed by TPA, however, the combination gave rise to 
an even greater inhibitory effect. The number of lymphocytes, monocytes and 
leukocytes (CD45+ cells) in the dermis were also significantly inhibited by the 
combination of UA + Res compared to the individual compounds alone. The greater 
inhibition of inflammation by the combination of UA + Res was likely due to the 
greater inhibition of inflammatory signaling pathways and to a greater reduction in 






In conclusion, the current study shows for the first time the efficacy of a combination 
of UA + Res for inhibition of tumor promotion in mouse skin. This combination of UA 
+ Res produced a greater inhibition of skin tumor promotion by TPA compared to UA 
or Res alone. In addition, the combination targeted multiple TPA-induced signaling 
pathways involved in both epidermal proliferation and inflammation and produced 
effects on a number of these pathways greater than either compound alone. For the 
current experiments we choose to apply the compounds via the topical route. An 
important goal for future studies will be to examine the efficacy of this and other 
combinations, when given in the diet. Combining phytochemicals such as UA and 
Res appears to produce a CR mimetic type of effect by targeting multiple signaling 

















Chapter 5. Summary, significance and future studies 
Given the projections for increases in cancer incidence worldwide and cancer related 
morbidity and mortality as well as the high costs of cancer treatment, there remains 
an increasing interest and need to develop effective cancer prevention strategies. 
According to the World Health Organization (WHO), at least one third of all cancers 
can be prevented by controlling dietary factors, excessive body weight, and lack of 
physical activity. Numerous studies have shown that diet-induced obesity increases 
cancer risks and modifications of an individual‟s diet, such as increased consumption 
of fruits and vegetables, as well as increased physical activity, have been shown to 
be potentially effective interventions. However, it is very difficult to regulate these 
factors for a large portion of the population and a commitment of significant change 
in life style is often needed. In this regard, numerous studies have found agents that 
reverse, inhibit or delay the onset of early and in some cases even later stages of 
carcinogenesis [6]. In addition, considerable studies are being conducted to develop 
and/or identify agents which mimic some of the beneficial effects of CR on 
tumorigenesis. Therefore, the current studies focused natural compounds including 
triterpenes (UA, OA, AA, CA, 3-epiCA, MA, and 3-epiMA) from P. frutescens and Res 
(from a variety of natural sources) for possible cancer chemopreventive effects and 
CR mimetic activity on tumorigenesis. Although UA and Res have been widely 
studied for their anti-tumorigenic effect in many cancer models including the skin 
tumor model, the efficacy of the other listed triterpenenoid compounds have not yet 
been tested or studied in great detail in animal models of cancer.  
 
As noted, a number of studies have discovered phytochemicals (e.g., UA, Res, 





models. However, phytochemicals given as single agents may not be efficacious 
cancer preventive agents, especially in large populations of genetically diverse 
individuals. Considering they have relatively low specificity against single target 
proteins and low toxicity when compared with synthetic compounds, combining 
phytochemicals may be more advantageous for cancer prevention. In this regard, a 
number of studies support the hypothesis that combining of phytochemicals might be 
good strategy for a greater chemopreventive effectiveness [174, 175]. Therefore, the 
hypothesis of current study was that combining agents may provide the most rational 
and effective approach to cancer chemoprevention and provide overall effects that 
more similarly mimic the effects seen with CR. CR has been shown to inhibit 
tumorigenesis in many different cancer models regardless of the mode of tumor 
induction [210]. Therefore, in addition to evaluating a broader range of triterpenes for 
chemopreventive activity, this project also combined two well-established 
phytochemicals, UA and Res, for their possible combinatorial cancer 
chemopreventive effect in skin tumor promotion during two-stage skin 
carcinogenesis in mice. 
 
In the current project, we conducted a comprehensive evaluation of the inhibitory 
effects of UA and a series of related triterpenes including OA, AA, CA, 3-epiCA, MA, 
and 3-epiMA from P. frutescens on skin tumor promotion. Several of the compounds 
were evaluated for the first time including, CA, 3-epiCA, MA, and 3-epiMA. Further 
studies explored in detail potential mechanisms for the tumor promotion inhibitory 
activity of this group of compounds. All of the triterpenes evaluated effectively 
inhibited skin tumor promotion by TPA at the dose used. Notably, several of the 





development when compared to UA, a prototype triterpene which has been more 
widely studied for its cancer chemopreventive activity. All compounds also inhibited 
TPA-induced infiltrated inflammatory cells in dermis, inflammatory gene expression, 
and epidermal hyperproliferation. Again, 3-epiCA and MA were found to have the 
greatest inhibitory effect on tumor promotion and produced greater inhibitory effects 
on these responses induced by TPA that are essential for the process of tumor 
promotion. AMPK is activated in response to CR and increasing evidence has 
suggested that AMPK activators are potent inhibitors in chemically- or UV-induced 
skin cancer. Our data indicate that all triterpene compounds at the dose tested 
(excluding UA) significantly activated AMPK. These results also support the 
hypothesis that triterpene compounds have CR mimetic activity. Overall, the findings 
related to the triterpenes found in P. frutescens suggest that further evaluation of 
these compounds is warranted and that several compounds, in particular, 3-epiCA 
and MA would be very attractive candidates for further investigation. 
 
The current data also indicate that combining agents such as UA (a pentacyclic 
triterpene) and Res (a phytoalexin) is a valid approach for achieving greater 
chemopreventive activity. As shown in Chapter 4, topical pretreatment with the 
combination of UA + Res with inhibited skin tumor promotion by TPA as shown by 
significant decreases in both tumor multiplicity and tumor size to a greater extent 
than with either compound alone. Also, the combination of UA + Res produced a 
greater inhibition of both cellular (epidermal hyperproliferation and skin inflammation) 
and biochemical/molecular (expression of inflammatory cytokines, cell signaling and 
transcription factor activity) changes associated with the process of skin tumor 





important role in preventing skin tumorigeneiss. The combination of UA + Res 
induced a dramatic increase of p-AMPK-Thr172. Collectively, the data indicate that the 
combination of UA + Res is an effective inhibitor of skin tumor promotion which has a 
greater chemopreventive activity and has activity that resembles some of the effects 
of CR. It is also important to point out that this combination was more effective in 
mice maintained on either a 10 Kcal % fat (overweight control diet) or a 60 Kcal % fat 
diet (obesity-inducing diet) producing mice with overweight and obese body 
phenotypes, respectively. The data indicate combinations such as the one used in 
our current studies may be useful in an obese setting where risk reduction is needed 
but where rapid weight loss cannot be effectively achieved.     
 
With constant efforts to elucidate mechanisms of CR in tumorigenesis and to identify 
target proteins for cancer chemoprevention studies, various mechanisms have been 
discovered that are attributed to cancer chemopreventive agents. It is clear that 
multiple signaling pathways are known to be involved in the effects of CR during 
cancer development. Furthermore, obesity increases cancer risks by inducing 
inflammatory responses leading to tumor development. Thus, targeting multiple 
signaling pathways and inflammatory responses simultaneously appears to be the 
most rational approach for achieving chemopreventive efficacy. Since the triterpene 
compounds tested in this study displayed inhibitory effects against multiple signaling 
pathways, skin inflammation, and proinflammatoy cytokines in response to TPA, we 
were able to conclude that the triterpenes found in P. frutescens possess good 
chemopreventive activity and CR mimetic activity. Although all of the compounds 
triterpenes studied had some overlapping activity, each of the compounds also 





example, our data indicate that while UA did not further activate AMPK, the other 
triterpenes examined did further activate AMPK when given with TPA.  Furthermore, 
several of the compounds, notably 3-epiCA and MA, inhibited some signaling 
pathways (i.e., IGF-1R) not significantly inhibited by the other triterpenes. The 
structural features that lead to these differences in activity among the triterpenes are 
not known at the present time but would seem an interesting area for further 
research. In addition, although UA did not activate AMPK when given by itself with 
TPA, Res significantly increased AMPK activation. However, the combination of UA + 
Res exhibited a dramatic activation of AMPK. Hence, combining agents may lead to 
potentiated effects not only on signaling pathways but also on inhibition of 
carcinogenesis that warrants further evaluation.  
 
Overall, the present data support the hypothesis that triterpenes alone or in 
combination with other chemicals such as Res act like a CR mimetic by modulating 
growth factor signaling, inflammatory signaling, skin inflammation, and inflammatory 
cytokines in relation to inhibitory effects on skin tumor development. Further study of 
CR mimetic combinations could lead to identification of combinations that would be 
suitable for use in human populations especially high risk populations as a cancer 
chemoprevention strategy. 
 
Ongoing and future studies 
Future experiments will explore the efficacy of 3-epiCA and MA that appeared to 
possess the greatest anti-tumor promotion effects in this project. For future studies, 
these compounds will be given in a diet at various dosages (e.g., 0, 1.0, 10.0 g/kg) 





their ability to inhibit skin tumor promotion by TPA. In this study, we will be able to 
see the efficacy of dietary administration of the compounds on skin tumor promotion. 
The dietary efficacy of these compounds will also be compared with that of UA. 
Bioavailability of these compounds will be determined as assessed by serum 
analysis of the parent compounds and treatment with several doses of UA, 3-epiCA 
and MA will allow us to establish a dose-response relationship. In addition, 
comparisons of their efficacy between control and obese mice will provide better 
evaluation of their effects in obese mice on skin tumor formation. Data generated as 
part of our completed study demonstrated that UA and related compounds 
differentially regulated multiple signaling pathways. STAT3 signaling is one of the 
most affected pathways by several compounds including CA, 3-epiCA, MA, and 3-
epiMA. Therefore downstream molecules such as c-myc, Bcl-xL, survivin, bcl-2, and 
cyclin D1 in addition to Twist1 will be further evaluated. We also observed significant 
activation in AMPK and its direct downstream target, Ulk1 S555, which is responsible 
for activation of the autophagic pathway, by pretreatment with AA, CA, 3-epiCA, MA, 
and 3-epiMA. Therefore, further evaluation of this pathway in the chemopreventive 
effects of these compounds will be conducted by analyzing autophagic molecules 
including Atg5, beclin1, and LC3IIB. In addition to Western blot analysis, electron 
microscopy and immunofluorescence assays will allow for better evaluation of 
compound efficacy on autophagosome formation. 
  
In ongoing experiments, the ability of UA in combination with another widely-studied 
chemopreventive agent, curcumin, is being evaluated for possible inhibition of skin 
tumor promoting. The combination of UA + curcumin (various doses) is being applied 





synergistic effects on inhibiting TPA-induced epidermal signaling pathways including 
Akt/mTORC1, p38 MAPK, JNK1/2, NF-B, and AMPK. In addition, the effect of UA + 
curcumin will be evaluated on TPA-induced epidermal hyperproliferation and skin 
inflammation. Lastly, the ability of UA + curcumin to act additively or synergistically at 
inhibiting skin tumor promotion will be examined. Preliminary data suggest that this 
combination also has greater ability than either agent alone to inhibit epidermal 
proliferation and signaling induced by TPA. 
 
In another ongoing experiment, the dietary effect of UA (2 g/kg of AIN76A diet) in 
combination with Res (5g/kg of AIN76A diet) or curcumin (10g/kg of ANI76A diet) on 
short-term markers of skin tumor promotion is being evaluated. Bioavailability of 
these combinations will be determined based on measurement of their amount in 
sera. The multiple signaling pathways identified to be affected by the combination of 
topical UA + Res will be also explored for this study. The effect of UA in combination 
with Res or curcumin on TPA-induced epidermal thickness, LI, and expression of 
inflammatory cytokines will be investigated. Thus, results from short-term 
experiments will provide comprehensive mechanisms in relation to anti-tumor 
promoting effect. Finally, two-stage carcinogenesis experiment will be conducted to 
evaluate the effect of oral administration with UA + Res or UA + curcumin on skin 
tumor promotion by TPA. Hence, our ongoing and further experiments will allow us to 
identify potential chemopreventive agent combinations administered in the diet and 
the results obtained from these experiments may allow further assessment as to the 
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